false
0001393434
0001393434
2024-02-20
2024-02-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 20, 2024
OCULAR THERAPEUTIX, INC.
(Exact Name of Company as Specified in Charter)
Delaware |
|
001-36554 |
|
20-5560161 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
24 Crosby Drive
Bedford, MA 01730
(Address of Principal Executive Offices)
(Zip Code)
Company’s telephone number, including area
code: (781) 357-4000
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of
each exchange on which
registered |
Common Stock, $0.0001 par value per share |
|
OCUL |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 |
Entry into a Material Definitive Agreement. |
Securities Purchase Agreement
On February 21, 2024, Ocular Therapeutix, Inc., a Delaware
corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”)
with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell
to the Investors in a private placement an aggregate of 32,413,560 shares of the Company’s common stock, par value $0.0001 per share
(the “Shares”), at a price of $7.52 per share and, to certain Investors in lieu of Shares, pre-funded warrants to purchase
10,805,957 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $7.519 per Pre-Funded Warrant
(the “Private Placement”).
The Private Placement is expected to close on or about February 26,
2024, subject to the satisfaction of certain customary closing conditions. The Company expects to receive aggregate gross proceeds from
the Private Placement of approximately $325.0 million, before deducting placement agent fees and offering expenses.
BofA Securities acted as sole placement agent for the Private Placement.
The Company has granted the Investors indemnification rights with respect
to its representations, warranties, covenants and agreements under the Securities Purchase Agreement.
Pre-Funded Warrants
Each Pre-Funded Warrant to be issued in the Private Placement will
have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised
in full.
Under the terms of the Pre-Funded Warrants, the Company may not effect
the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant,
if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with
its affiliates, any other persons acting as a group together with the holder or any of the holder’s affiliates, and any other persons
whose beneficial ownership of common stock would or could be aggregated with the holder’s for purposes of Section 13(d) or
Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) would exceed 4.99% or 9.99%, at the
option of the holder, of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage
ownership is determined in accordance with the terms of such Pre-Funded Warrant, which percentage may be increased or decreased at the
holder’s election upon 61 days’ notice to the Company subject to the terms of such Pre-Funded Warrants, provided that such
percentage may in no event exceed 19.99%.
Registration Rights Agreement
Also on February 21, 2024, the Company entered into a registration
rights agreement (the “Registration Rights Agreement”) with the Investors, pursuant to which the Company agreed to register
for resale the Shares and the shares of the Company’s common stock issuable upon exercise of the Pre-Funded Warrants (the “Pre-Funded
Warrant Shares” and, together with the Shares, the “Registrable Securities”). Under the Registration Rights Agreement,
the Company has agreed to file a registration statement covering the resale by the Investors of their Registrable Securities no later
than 30 days following the closing of the Private Placement (the “Filing Deadline”). The Company has agreed to use commercially
reasonable efforts to cause such registration statement to be declared effective, if not automatically effective upon filing, as soon
as practicable and to keep such registration statement effective until the earlier of (i) the date that all Registrable Securities
covered by such registration statement have been sold or can be sold without restriction pursuant to Rule 144 and without the requirement
to be in compliance with Rule 144(c)(1) (or any successor thereof) promulgated under the Securities Act of 1933, as amended
(the “Securities Act”), and (ii) five years after the closing of the Private Placement. The Company has agreed to be
responsible for all fees and expenses incurred in connection with the registration of the Registrable Securities.
In the event (i) the registration statement has not been filed
by the Filing Deadline, (ii) the registration statement is not automatically effective upon filing or not declared effective prior
to the earliest of (a) five business days after the date on which the Company is notified by the Securities and Exchange Commission
(the “SEC”) that the registration statement will not be reviewed by the SEC staff or is not subject to further comment by
the SEC staff, (b) the 60th day following the closing of the Private Placement, if the SEC staff determines not to review
the registration statement, or (c) the 90th day following the closing of the Private Placement, if the SEC staff determines
to review the registration statement, or (iii) after the registration statement has been declared effective by the SEC, sales cannot
be made pursuant to the registration statement for any reason, subject to certain limited exceptions, then the Company has agreed to make
pro rata payments to each Investor as liquidated damages in an amount equal to 1% of the aggregate amount invested by each such Investor
in the Registrable Securities per 30-day period or pro rata for any portion thereof for each such 30-day period during which such event
continues, subject to certain caps set forth in the Registration Rights Agreement.
The Company has granted the Investors customary indemnification rights
in connection with the registration statement. The Investors have also granted the Company customary indemnification rights in connection
with the registration statement.
The foregoing descriptions of the Securities Purchase Agreement, the
Pre-Funded Warrants and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference
to the full text of the Securities Purchase Agreement, the form of Pre-Funded Warrant and the Registration Rights Agreement, copies of
which are filed as Exhibits 10.1, 4.1 and 10.2 hereto, respectively, and incorporated by reference herein.
The representations, warranties and covenants contained in the Securities
Purchase Agreement and the Registration Rights Agreement were made solely for the benefit of the parties thereto and the placement agent
expressly named as third-party beneficiary thereto and may be subject to limitations agreed upon by the contracting parties. Accordingly,
the Securities Purchase Agreement and the Registration Rights Agreement are incorporated herein by reference only to provide investors
with information regarding the terms thereof and not to provide investors with any other factual information regarding the Company or
its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the
SEC.
Item 2.02 |
Results of Operations and Financial Condition. |
Although the Company is currently in the process of finalizing its
financial results for the quarter and year ended December 31, 2023, its preliminary, unaudited cash and cash equivalents were approximately
$195.8 million as of December 31, 2023, and its preliminary, unaudited net product revenue for the year ended December 31, 2023,
was approximately $57.9 million. The estimated net product revenue and cash and cash equivalents figures are based on preliminary and
unaudited information and management’s estimates as of the date of this Current Report on Form 8-K and are subject to completion
of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted
an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated net product revenue
or cash and cash equivalents figures.
The information in Item 2.02 of this Current Report on Form 8-K
shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
Item 3.02 |
Unregistered Sales of Equity Securities. |
The information contained above in Item 1.01 is hereby incorporated
by reference into this Item 3.02. Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering
and sale of the Shares and the Pre-Funded Warrants is being conducted pursuant to an exemption from registration under Section 4(a)(2) of
the Securities Act. The Shares and Pre-Funded Warrants have not been registered under the Securities Act or any state securities laws,
and the Shares and Pre-Funded Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable
exemption from the registration requirements. The sale of the securities will not involve a public offering and will be made without general
solicitation or general advertising. The Investors represented that they are institutional “accredited investors” as defined
in Rule 501(a)(1), (2), (3) or (7) under the Securities Act or “qualified institutional buyers” within the
meaning of Rule 144A under the Securities Act, and that they are acquiring the Shares and Pre-Funded Warrants for investment purposes
only and not with a view to any resale, distribution or other disposition of the Shares and Pre-Funded Warrants in violation of the United
States federal securities laws.
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Appointment of Pravin U. Dugel, M.D., as Executive Chairman
On February 20, 2024, Pravin U. Dugel, M.D., was appointed as
Executive Chairman of the Company and as a Class III director, effective as of February 21, 2024, to serve until the 2026 annual
meeting of the stockholders of the Company and thereafter until his successor has been duly elected and qualified, or until his earlier
death, resignation or removal.
On February 21, 2024, the Company entered into an employment agreement
with Dr. Dugel (the “Dugel Agreement”). Under the Dugel Agreement, Dr. Dugel is entitled to receive an annual base
salary of $540,000 and an annual cash bonus, determined by and payable at the sole discretion of the board of directors of the Company
(the “Board”), targeted at 65% of his annual base salary, and to participate in the employee benefit programs generally available
to employees of the Company.
Pursuant to the Dugel Agreement, the Company agreed to grant to Dr. Dugel,
effective February 22, 2024 (the “Grant Date”), (i) a non-statutory stock option to purchase up to 1,282,469 shares
of the Company’s common stock at a per share exercise price equal to the closing price of the Company’s common stock on The
Nasdaq Global Market on the Grant Date (the “Dugel Option Award”) and (ii) a restricted stock unit award representing
the right to receive 854,979 shares of the Company’s common stock (the “Dugel RSU Award” and, together with the Dugel
Option Award, the “Dugel Equity Awards”). Subject to Dr. Dugel’s continued employment with the Company, the Dugel
Option Award will vest in equal monthly installments over a four-year period, and the Dugel RSU Award will vest in equal quarterly installments
over a three-year period.
Under the Dugel Agreement, the Company agreed that, in the event that
Dr. Dugel’s employment is terminated by the Company without “cause” or if Dr. Dugel resigns for “good
reason” (as such terms are defined in the Dugel Agreement), the Company will pay Dr. Dugel his base salary for a period of
twelve months; to the extent allowed by applicable law and the terms of the applicable policies, continue to provide him and his eligible
dependents with group health insurance for a period of up to twelve months; and accelerate the vesting of his time-based equity awards
outstanding at the time of his separation by twelve months or, in the case of the Dugel Equity Awards, twenty-four months. The Company
also agreed that, in the event that Dr. Dugel’s employment is terminated by the Company without “cause” or if Dr. Dugel
resigns for “good reason” during the period commencing three months prior to, and ending twelve months following, a “corporate
change,” the Company will pay him an amount equal to the sum of his base salary then in effect for 18 months and an amount equal
to one and one-half times his target annual bonus for the year of termination, in a lump sum; to the extent allowed by applicable law
and the terms of the applicable policies, continue to provide him and his eligible dependents with group health insurance for a period
of up to 18 months; and accelerate in full the vesting of all outstanding time-based equity awards held by him. Upon any termination of
Dr. Dugel without “cause” or if he resigns for “good reason,” the Dugel Option Award will be exercisable
for up to 24 months post-separation.
These severance benefits are subject to the execution and effectiveness
of a general release of claims in favor of the Company and its affiliates.
The Dugel Agreement also includes standard invention, non-disclosure,
non-competition, and non-solicitation provisions.
Dr. Dugel, age 60, most recently served as President of Iveric
bio, Inc. (“Iveric”), a biopharmaceutical company, from May 2021 to October 2023. Iveric was publicly traded
until the closing of its merger with Astellas Pharma Inc. in July 2023. Prior to his time as President of Iveric, Dr. Dugel
served as Iveric’s Executive Vice President, Chief Strategy and Business Officer from April 2020 to May 2021 and as a
managing partner at Retinal Consultants of Arizona from 1994 to 2019. Dr. Dugel serves on the board of Oculis Holding AG, a publicly
traded biopharmaceutical company, and previously served on the boards of Iveric from January 2023 until its acquisition by Astellas
and Aerpio Pharmaceuticals, Inc. from March 2017 until its acquisition by Aadi Bioscience, Inc. in August 2021. Dr. Dugel
also served as a clinical professor at the USC Eye Institute in the Keck School of Medicine at the University of Southern California and
was a founding member of the Spectra Eye Institute in Sun City, Arizona. Dr. Dugel holds a B.A. from Columbia University in Comparative
Literature and Molecular Biology and an M.D. from the UCLA School of Medicine, and he completed his residency in ophthalmology at the
USC Eye Institute. He completed a medical retina fellowship at the Bascom Palmer Eye Institute and a surgical eye fellowship at the USC
Eye Institute.
Dr. Dugel has no family relationship with any of the executive
officers or directors of the Company. There are no arrangements or understandings between Dr. Dugel and any other person pursuant
to which he is being appointed as an executive officer of the Company or elected as a director of the Company.
In connection with his appointment as an officer and director of the
Company, Dr. Dugel will enter into the Company’s standard form of Indemnification Agreement, a copy of which was filed as Exhibit 10.12
to the Company’s Registration Statement on Form S-1 (File No. 333-196932) filed with the SEC on June 20, 2014. Pursuant
to the terms of such indemnification agreement, the Company may be required, among other things, to indemnify Dr. Dugel for expenses,
including attorneys’ fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his
service to the Company.
Transition of Jeffrey S. Heier, M.D., from the Board to Chief Scientific
Officer of the Company
On February 21, 2024, the Company entered into an employment agreement
with Jeffrey S. Heier, M.D. (the “Heier Agreement”), under which Dr. Heier agreed to serve as Chief Scientific Officer
of the Company on a part-time basis, working 50% of a full-time schedule. In connection with entering into the Heier Agreement, the consulting
agreement between the Company and Heier Consulting, LLC, an entity affiliated with Dr. Heier, dated October 17, 2022, was terminated.
In addition, in connection with his commencement of employment, Dr. Heier
also resigned from the Board, effective February 21, 2024. At the time of his resignation, Dr. Heier informed the Company that
his resignation was not based upon any disagreement with the Board, or with the management of the Company, on any matter relating to the
Company’s operations, policies or practices.
Amendment of Antony Mattessich Employment Agreement
On February 21, 2024, the Company entered into an amendment (the
“Mattessich Amendment”) to its employment agreement with Antony Mattessich, the Company’s President and Chief Executive
Officer (as amended by the Mattessich Amendment, the “Mattessich Agreement”).
Under the Mattessich Amendment, the Company agreed that, in the event
that Mr. Mattessich’s employment is terminated by the Company without “cause” or if Mr. Mattessich resigns
for “good reason” (as such terms are defined in the Mattessich Agreement), the Company will pay Mr. Mattessich his base
salary for a period of 24 months; to the extent allowed by applicable law and the terms of the applicable policies, continue to provide
him and his eligible dependents with group health insurance for a period of up to 18 months; and accelerate the vesting of his time-based
equity awards outstanding at the time of his separation by twelve months or, in the case of all time-based equity awards granted to Mr. Mattessuch
prior to February 21, 2024 (the “Mattessich Legacy Awards”), twenty-four months. The Company also agreed that, in the
event that Mr. Mattessich’s employment is terminated by the Company without “cause” or if Mr. Mattessich resigns
for “good reason” during the period commencing three months prior to, and ending twelve months following, a “corporate
change,” the Company will pay him an amount equal to the sum of his base salary then in effect for 24 months and an amount equal
to two times his target annual bonus for the year of termination, in a lump sum; to the extent allowed by applicable law and the terms
of the applicable policies, continue to provide him and his eligible dependents with group health insurance for a period of up to 18 months;
and accelerate in full the vesting of all outstanding time-based equity awards held by him. Upon any termination of Mr. Mattessich
without “cause” or if he resigns for “good reason,” the Mattessich Legacy Awards that are options shall be exercisable
for 24 months post-separation.
These severance benefits are subject to the execution and effectiveness
of a general release of claims in favor of the Company and its affiliates.
Appointment of Charles Warden as Lead Independent Director
On February 20, 2024, the Board appointed Charles Warden to serve
as Lead Independent Director of the Board, effective upon Dr. Dugel’s election to the Board.
Amendment of 2019 Inducement Stock Incentive Plan
On February 20, 2024, the Board amended the 2019 Inducement Stock
Incentive Plan, as amended, to increase the aggregate number of shares issuable thereunder from 1,054,000 to 3,804,000 shares of common
stock (the “Plan Amendment”).
The foregoing descriptions of the Dugel Agreement, the Mattessich
Amendment, and the Plan Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of
the Dugel Agreement, the Mattessich Amendment and the Plan Amendment, copies of which are filed as Exhibits 10.3, 10.4, and 10.5
hereto, respectively, and are incorporated by reference herein.
Additional Officer Appointments
On February 21, 2024, the Company entered into an employment agreement
with Sanjay Nayak, MBBS, Ph.D., providing for Dr. Nayak to serve as Chief Strategy Officer of the Company.
On February 21, 2024, the Company entered into an employment agreement
with Peter Kaiser, M.D., who previously served as Chief Medical Advisor—Retina to the Company, under which Dr. Kaiser agreed
to serve as Medical Director of the Company on a part-time basis, working 50% of a full-time schedule.
Press Release Regarding Private Placement
On February 22, 2024, the Company issued a press release announcing
the Private Placement. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1
to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
4.1 |
|
Form of Pre-Funded Warrant |
|
|
|
10.1 |
|
Securities Purchase Agreement, dated February 21, 2024, by and among the Company and the other parties thereto |
|
|
|
10.2 |
|
Registration Rights Agreement, dated February 21, 2024, by and among the Company and the other parties thereto |
|
|
|
10.3 |
|
Employment Agreement, by and between the Company and Dr. Pravin U. Dugel, dated as of February 21, 2024 |
|
|
|
10.4 |
|
Amendment to Employment Agreement, by and between the Company and Antony Mattessich, dated as of February 21, 2024 |
|
|
|
10.5 |
|
Amendment No. 2 to 2019 Inducement Stock Incentive Plan |
|
|
|
99.1 |
|
Press Release, dated February 22, 2024 |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
OCULAR THERAPEUTIX, INC. |
|
|
|
Date: February 22, 2024 |
By: |
/s/ Donald Notman |
|
|
Donald Notman |
|
|
Chief Financial Officer |
Exhibit 4.1
Execution Version
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS
EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.
PRE-FUNDED COMMON STOCK PURCHASE WARRANT
OCULAR THERAPEUTIX, INC.
Warrant Shares: _______ |
|
Initial Exercise Date: February ___, 2024
Issue Date: February ___, 2024 |
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT
(the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the “Initial Exercise Date”) until exercised in full (the “Termination Date”) but
not thereafter, to subscribe for and purchase from Ocular Therapeutix, Inc., a Delaware corporation (the “Company”),
up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price
of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Section 1. Definitions. Capitalized terms used and not
otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”),
dated February 21, 2024, among the Company and the purchasers signatory thereto (the “Purchasers”).
Section 2. Exercise.
a) Exercise of Warrant. Exercise of the
purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date
and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment)
of the Notice of Exercise in the form annexed hereto, and delivered in accordance with the notice requirements set forth in Section 5(h) (the
“Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price (as defined below) for the Warrant Shares specified in the applicable Notice of
Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below
is applicable and specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any
medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder
shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and
the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt
of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.
b) Exercise Price. The aggregate exercise
price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded to the Company on or prior to the
Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001 per Warrant Share)
shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the
return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever,
including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid exercise price per
share of Common Stock under this Warrant shall be $0.001, subject to adjustment hereunder (the “Exercise Price”).
c) Cashless Exercise. This Warrant may
also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled
to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:
(A) = as applicable: (i) the VWAP (as defined below) on the
Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and
delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of
Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price (as defined below)
of the Common Stock on the Principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the
applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is
delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours”
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if
the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof
after the close of “regular trading hours” on such Trading Day;
(B) = the Exercise Price of this Warrant, as adjusted hereunder;
and
(X) = the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a
cashless exercise.
If Warrant Shares are issued in such a cashless exercise, the parties
acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics
of the Warrants being exercised, and for purposes of Rule 144 under the Securities Act, the holding period of the Warrant Shares
being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c),
except to the extent required by applicable law, rule or regulation.
“Bid Price” means, for any date, the price determined
by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid
price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is
then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New
York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading
on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases,
the fair market value of a share of Common Stock as determined in good faith by the Board of Directors of the Company.
“VWAP” means, for any date, the price determined
by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common
Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in
all other cases, the fair market value of a share of Common Stock as determined by the Board of Directors of the Company and reasonably
agreed to by the Purchasers of a majority in interest of the Warrants then outstanding.
d) Mechanics of Exercise.
i. Delivery
of Warrant Shares Upon Exercise. Provided the Company has received the aggregate Exercise Price from the Holder (other than in the
case of a cashless exercise), the Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to
the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through
its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company’s transfer agent is then a participant
in such system and either (A) there is an effective registration statement covering the resale of the Warrant Shares by the Holder
or (B) in the case of a cashless exercise of the Warrant, the Warrant Shares are eligible for resale by the Holder without volume
or manner-of-sale limitations pursuant to Rule 144, and in each case, at the request of the Holder, in electronic book entry form
to the account of the Holder or by physical delivery of a certificate, registered in the Company’s share register in the name of
the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is not later than the number of Trading Days comprising the Standard
Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of
(i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery
to the Company of the Notice of Exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so
long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard
settlement period, expressed in a number of Trading Days, on the Principal Trading Market with respect to the Common Stock as in effect
on the date of delivery of the Notice of Exercise.
ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights
of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be
identical with this Warrant.
iii. Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above
pursuant to an exercise on or before the Warrant Share Delivery Date (other than a failure solely caused by incorrect or incomplete information
provided by the Holder to the Company), and if after such date the Holder is required by its broker to purchase (in an open market transaction
or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by
the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company
shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price
at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate
the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise
shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely
complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required
to pay the Holder $1,000. The Holder shall provide the Company written notice within two (2) Trading Days after the occurrence of
a Buy-In indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to
timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.
iv. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.
v. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall, to the
extent applicable, pay all Transfer Agent fees required for processing of any Notice of Exercise and all fees to the Depository Trust
Company (or another established clearing corporation performing similar functions) required for electronic delivery of the Warrant Shares.
vii. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
e) Holder’s Exercise Limitations.
The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant,
pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable
Notice of Exercise, the Holder (together with (i) the Holder’s Affiliates, (ii) any other Persons acting as a group together
with the Holder or any of the Holder’s Affiliates, and (iii) any other Persons whose beneficial ownership of the Common Stock
would or could be aggregated with the Holder’s for purposes of Section 13(d) or Section 16 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) (such Persons set forth in clause (i) through (iii) above, “Attribution
Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the
number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall
exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of
this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Attribution Parties. For purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules or forms required to be filed in accordance therewith. To the extent that the limitation contained in this
Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e),
in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock
as reflected in (A) the Company’s most recent periodic or annual report filed with the SEC, as the case may be, (B) a
more recent public announcement by the Company or (C) a more recent written notice from the Company or the Transfer Agent to the
Holder setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall
within one (1) Trading Day confirm in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The “Beneficial Ownership Limitation” shall be [4.99%][9.99]% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this
Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e),
provided that the revised Beneficial Ownership Limitation in no event exceeds 19.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase or decrease in the Beneficial Ownership Limitation will not be effective
until the 61st day after such notice is delivered to the Company. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.
Notwithstanding anything to the contrary contained herein, the Company
shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares
in excess of that number of Warrant Shares which, upon giving effect to such exercise, would cause (i) the aggregate number of shares
of Common Stock beneficially owned by the Holder and its Attribution Parties to exceed 19.99% of the total number of issued and outstanding
shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company
beneficially owned by the Holder and its Attribution Parties to exceed 19.99% of the combined voting power of all of the securities of
the Company then outstanding following such exercise. For purposes of this Section 2(e), the aggregate number of shares of Common
Stock or voting securities beneficially owned by the Holder and its Attribution Parties shall include the shares of Common Stock issuable
upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common
Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder
and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company
that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire
at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at
any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject
to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any
of its Attribution Parties.
Section 3. Certain Adjustments.
a) Stock Dividends and Splits. If the Company,
at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares
of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt,
shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares
of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common
Stock into a smaller number of shares of Common Stock, or (iv) issues by reclassification of shares of the Common Stock any shares
of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.
b) Pro Rata Distributions. During such
time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights
to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution; provided, however, that, to the extent
that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation.
c) Fundamental Transaction. If, at any
time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any
merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related
transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person)
is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of more than 50% the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock
(not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with
the other Persons making or party to, such stock or share purchase agreement or other business combination) and in connection with such
transaction the Common Stock is converted into or exchanged for other securities, cash or property (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the securities, cash and other property of the successor
or acquiring corporation (or ultimate parent thereof) or of the Company, if it is the surviving corporation, as applicable, (the “Alternate
Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for
which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on
the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”)
to assume in writing all of the obligations of the Company under this Warrant prior to such Fundamental Transaction in accordance with
the provisions of this Section 3(d) and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for the Alternate Consideration, and with an exercise price which applies the exercise price hereunder to such Alternate
Consideration (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the
value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction) and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.
d) Calculations. All calculations under
this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3,
the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of
Common Stock (excluding treasury shares, if any) issued and outstanding.
e) Notice to Holder.
i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
ii. Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (and all of its subsidiaries, taken as
a whole) is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email
to the Holder at its last email address as it shall appear upon the Warrant Register (as defined below), at least 20 calendar days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which
the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file
such notice with the SEC pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.
Section 4. Transfer of Warrant.
a) Transferability. Subject to compliance
with any applicable securities laws and the conditions set forth in Section 4(d) hereof, this Warrant and all rights hereunder
(including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the
principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form
attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making
of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment,
and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly
be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company
within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in
full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued.
b) New Warrants. This Warrant may be divided
or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying
the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance
with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver
a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants
issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except
as to the number of Warrant Shares issuable pursuant thereto.
c) Warrant Register. The Company shall
register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the
name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary.
d) Transfer Restrictions. If, at the time
of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered
pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible
for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company
may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with
the provisions of Section 9.1 of the Purchase Agreement.
e) Representation by the Holder. The Holder,
by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant
Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or
any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted
under the Securities Act.
Section 5. Miscellaneous.
a) No Rights as Stockholder Until Exercise;
No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of
the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without
limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to
receive cash payments pursuant to Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise
of this Warrant.
b) Loss, Theft, Destruction or Mutilation of
Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction
or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity
or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender
and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate
of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.
c) Saturdays, Sundays, Holidays, etc.
If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading
Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.
d) Authorized Shares.
The Company covenants that, during the period
the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for
the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its
issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary
to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon
the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant
and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).
Except and to the extent as waived or consented
to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through
any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in
the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder
as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase
the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value
and (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid
and nonassessable Warrant Shares upon the exercise of this Warrant.
e) Governing Law. All questions concerning
the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance
with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that
all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant shall be
commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it
under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence
an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall
be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.
f) Restrictions. The Holder acknowledges
that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise,
will have restrictions upon resale imposed by state and federal securities laws.
g) Nonwaiver and Expenses. No course of
dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise
prejudice the Holder’s rights, powers or remedies (notwithstanding the fact that the right to exercise this Warrant terminates on
the Termination Date). Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as
shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.
h) Notices. Any and all notices or other
communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in
writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at
24 Crosby Drive, Bedford, Massachusetts 01730, Attn: Chief Financial Officer, [*], or such other email address or address
as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be
provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice
or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New
York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered
via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York
City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.
i) Limitation of Liability. No provision
hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration
herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common
Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.
j) Remedies. The Holder, in addition to
being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights
under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach
by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance
that a remedy at law would be adequate.
k) Successors and Assigns. Subject to applicable
securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors
and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to
be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.
l) Amendment. This Warrant may be modified
or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder, on the other hand.
m) Severability. Wherever possible, each
provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition
or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.
n) Headings. The headings used in this
Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.
********************
(Signature Page Follows)
IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
|
|
|
OCULAR THERAPEUTIX, INC. |
|
|
|
|
By: |
|
|
|
Name: Donald Notman |
|
|
Title: Chief Financial Officer |
|
NOTICE OF EXERCISE
TO: OCULAR THERAPEUTIX, INC.
(1) The undersigned hereby elects to purchase
________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith
payment of the exercise price in full, together with all applicable transfer taxes, if any.
(2) Payment shall take the form of (check
applicable box):
[ ] in lawful money of the United States; or
[ ] if permitted, the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number
of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).
(3) Please issue said Warrant Shares in the
name of the undersigned or in such other name as is specified below:
(4) By its delivery of this Notice of Exercise,
the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially
own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange
Act of 1934, as amended) permitted to be owned under Section 2(e) of the Warrant to which this notice relates.
The Warrant Shares shall be delivered to the following DWAC Account
Number:
[SIGNATURE OF HOLDER]
Name of Investing Entity: |
|
|
Signature of Authorized Signatory of Investing Entity: |
|
|
Name of Authorized Signatory: |
|
|
Title of Authorized Signatory: |
|
|
ASSIGNMENT FORM
(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)
FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to
|
|
|
|
|
Name: |
|
|
|
|
|
|
|
|
|
(Please Print) |
|
|
|
|
|
Address: |
|
|
|
|
|
|
|
|
|
(Please Print) |
|
|
|
|
|
Phone Number: |
|
|
|
|
|
|
|
Email Address: |
|
|
|
|
|
|
|
Dated: _______________ __, ______ |
|
|
|
|
|
|
|
Holder’s Signature: |
|
|
|
|
|
|
|
Holder’s Address: |
|
|
|
|
Exhibit 10.1
SECURITIES PURCHASE AGREEMENT
This SECURITIES PURCHASE AGREEMENT (this “Agreement”)
is made and entered into as of February 21, 2024 by and among Ocular Therapeutix, Inc., a Delaware corporation (the “Company”),
and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
RECITALS
A. The Company and the Investors are executing
and delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions of Section 4(a)(2) of
the 1933 Act (as defined below);
B. The Investors wish to purchase from the Company,
and the Company wishes to sell and issue to the Investors, upon the terms and subject to the conditions stated in this Agreement, (1) an
aggregate of 32,413,560 shares (the “Shares”) of the Company’s Common Stock, par value $0.0001 per share (the
“Common Stock”), and (2) pre-funded warrants in the form attached hereto as Exhibit B to purchase
an aggregate of 10,805,957 shares of Common Stock (each, a “Pre-Funded Warrant” and collectively, the “Pre-Funded
Warrants”); and
C. Contemporaneously with the sale of the Shares
and Pre-Funded Warrants, the parties hereto will execute and deliver a Registration Rights Agreement, in the form attached hereto as Exhibit C
(the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain registration rights
in respect of the Shares and the Warrant Shares (as defined below) under the 1933 Act and applicable state securities laws.
In consideration of the mutual promises made herein
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree
as follows:
1. Definitions. For the purposes of this
Agreement, the following terms shall have the meanings set forth below:
“Affiliate” means, with respect
to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is controlled by, or is under
common Control with such Person.
“Business Day” means a day,
other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.
“Closing” has the meaning set
forth in Section 3.1.
“Closing Date” has the meaning
set forth in Section 3.1.
“Common Stock” has the meaning
set forth in the recitals to this Agreement.
“Common Stock Equivalents”
means any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation,
any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock.
“Company’s Knowledge”
means the actual knowledge as of the date hereof of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company
as of February 19, 2024.
“Control” (including the terms
“controlling,” “controlled by” or “under common control with”) means the possession, direct or indirect,
of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities,
by contract or otherwise.
“Disclosure Date” shall mean
February 22, 2024.
“DTC” means Depository Trust
Company.
“EDGAR system” has the meaning
set forth in Section 4.9.
“Environmental Laws” has the
meaning set forth in Section 4.15.
“GAAP” has the meaning set
forth in Section 4.17.
“Intellectual Property” has
the meaning set forth in Section 4.14.
“Material Adverse Effect” means
a material adverse effect on (i) the assets, liabilities, results of operations, financial condition or business of the Company and
its subsidiaries taken as a whole, (ii) the legality or enforceability of any of the Transaction Documents or (iii) the ability
of the Company to perform its obligations under the Transaction Documents, except that for purposes of Section 6.1(i) of this
Agreement, in no event shall a change in the market price of the Common Stock alone constitute a “Material Adverse Effect”.
“Material Contract” means any
contract, instrument or other agreement to which the Company is a party or by which it is bound that has been filed or was required to
have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.
“Nasdaq” means the Nasdaq Global
Market.
“Person” means an individual,
corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship,
unincorporated organization, governmental authority or any other form of entity not specifically listed herein.
“Placement Agent” means BofA
Securities, Inc.
“Placement Securities” means
the Shares and the Pre-Funded Warrants.
“Pre-Funded Warrants” has the
meaning set forth in the recitals to this Agreement.
“Press Release” has the meaning
set forth in Section 9.7(b).
“Principal Trading Market”
means the Trading Market on which the Common Stock is primarily listed on and quoted for trading, which, as of the date of this Agreement
and the Closing Date, shall be the Nasdaq Global Market.
“Registration Rights Agreement”
has the meaning set forth in the recitals to this Agreement.
“Regulation D” means Regulation
D as promulgated by the SEC under the 1933 Act.
“Required Investors” has the
meaning set forth in the Registration Rights Agreement.
“SEC” means the U.S. Securities
and Exchange Commission.
“SEC Filings” has the meaning
set forth in Section 4.8.
“Securities” means the Placement
Securities and the Warrant Shares.
“Shares” has the meaning set
forth in the recitals to this Agreement.
“Short Sales” means all “short
sales” as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be deemed to include the location and/or
reservation of borrowable shares of Common Stock).
“Trading Day” means (i) a
day on which the Common Stock is listed or quoted and traded on its Principal Trading Market or (ii) if the Common Stock is not quoted
on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported in the “pink sheets”
by OTC Markets Group Inc. (or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the
event that the Common Stock is not listed or quoted as set forth in (i) or (ii) hereof, then Trading Day shall mean a Business
Day.
“Trading Market” means whichever
of the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market
on which the Common Stock is listed or quoted for trading on the date in question.
“Transaction Documents” means
this Agreement, the Pre-Funded Warrants and the Registration Rights Agreement.
“Transfer Agent” has the meaning
set forth in Section 7.1(a).
“Warrant Shares” means the
shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.
“1933 Act” means the Securities
Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.
“1934 Act” means the Securities
Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.
2. Purchase and Sale of the Placement Securities.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company will issue and sell, and each Investor
will purchase, severally and not jointly, (a) the number of Shares set forth opposite the name of such Investor under the heading
“Number of Shares to be Purchased” on Exhibit A attached hereto, if any and (b) a Pre-Funded Warrant to purchase
the number of Warrant Shares set forth opposite the name of such Investor under the heading “Number of Warrant Shares Underlying
Pre-Funded Warrant Purchased” on Exhibit A attached hereto, if any. The purchase price per Share shall be $7.52. The
purchase price for the Pre-Funded Warrants shall be $7.519 per Warrant Share. The Pre-Funded Warrants shall have an exercise price equal
to $0.001 per Warrant Share.
3. Closing.
3.1. Upon the satisfaction or waiver of the conditions
set forth in Section 6, the completion of the purchase and sale of the Placement Securities (the “Closing”)
shall occur remotely via exchange of documents and signatures at a time (the “Closing Date”) to be agreed to by the
Company and the Investors but (i) in no event earlier than the second Business Day after the date hereof and (ii) in no event
later than the fifth Trading Day after the date hereof, and of which the Investors will be notified in advance by the Placement Agent.
3.2. On or before the Closing Date, each Investor
shall deliver or cause to be delivered to the Company, via wire transfer of immediately available funds pursuant to the wire instructions
delivered to such Investor by the Company on or prior to the Closing Date, an amount equal to the purchase price to be paid by the Investor
for the Placement Securities to be acquired by it as set forth opposite the name of such Investor under the heading “Aggregate Purchase
Price of Placement Securities” on Exhibit A attached hereto. If the Closing has not occurred for any reason on or prior
to the fifth Trading Day after the date hereof and the Agreement has been terminated by the Investor pursuant to Section 6.3, the
applicable purchase price shall be promptly (but not later than one Business Day thereafter) returned to the applicable Investor (if previously
wired by the applicable Investor to the Company).
3.3. At the Closing, the Company shall deliver
or cause to be delivered to each Investor (i) a number of Shares, registered in the name of the Investor (or its nominee in accordance
with its delivery instructions), equal to the number of Shares set forth opposite the name of such Investor under the heading “Number
of Shares to be Purchased” on Exhibit A attached hereto, if any and (ii) a Pre-Funded Warrant, registered in the
name of the Investor (or its nominee in accordance with its delivery instructions), to purchase up to the number of Warrant Shares set
forth opposite the name of such Investor under the heading “Number of Warrant Shares Underlying Pre-Funded Warrant Purchased”
on Exhibit A attached hereto, if any. The Shares shall be delivered via a book-entry record through the Company’s transfer
agent and the Company shall provide to each Investor evidence in form reasonably satisfactory to the Investor from the Transfer Agent
evidencing the issuance of such Shares. Unless the Company and an Investor otherwise mutually agree with respect to such Investor’s
Shares, at Closing settlement shall occur on a “delivery versus payment” basis.
4. Representations and Warranties of the Company.
The Company hereby represents and warrants to the Investors that, except (a) as described in the Company’s SEC Filings (as
defined below) or (b) as set forth on the disclosure schedule delivered herewith (which is arranged in numbered and lettered sections
corresponding to the numbered and lettered sections contained in this Section 4) (the “Disclosure Schedule”),
each of which qualify these representations and warranties in their entirety:
4.1. Organization, Good Standing and Qualification.
The Company is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation
and has all requisite corporate power and authority to carry on its business as now conducted and to own or lease its properties. The
Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of
its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has
not had and would not reasonably be expected to have a Material Adverse Effect. The Company’s subsidiaries are set forth on Exhibit 21.1
to its most recent Annual Report on Form 10-K, and the Company owns, directly or indirectly, 100% of the outstanding equity securities
of such subsidiaries. The Company’s subsidiaries are duly organized, validly existing and in good standing under the laws of their
jurisdiction of incorporation and have all requisite power and authority to carry on their business as now conducted and to own or lease
their properties. The Company’s subsidiaries are duly qualified to do business as foreign corporations and are in good standing
in each jurisdiction in which the conduct of their business or their ownership or leasing of property makes such qualification or leasing
necessary unless the failure to so qualify has not had and would not reasonably be expected to have a Material Adverse Effect.
4.2. Authorization. The Company has the
requisite corporate power and authority and has taken all requisite corporate action necessary for, and no further action on the part
of the Company, its officers, directors and stockholders is necessary for, (i) the authorization, execution and delivery of the Transaction
Documents, (ii) the authorization of the performance of all obligations of the Company hereunder or thereunder, and (iii) the
authorization, issuance (or reservation for issuance) and delivery of the Placement Securities. The Transaction Documents constitute the
legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’
rights generally and to general equitable principles.
4.3. Capitalization. The Company is authorized
under its Certificate of Incorporation to issue 200,000,000 shares of Common Stock. The Company’s disclosure of its issued and outstanding
capital stock in its most recent SEC Filing containing such disclosure was accurate in all material respects as of the date indicated
in such SEC Filing. All of the issued and outstanding shares of the Company’s capital stock have been duly authorized and validly
issued and are fully paid and nonassessable; none of such shares were issued in violation of any preemptive rights; and such shares were
issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties. No Person
is entitled to preemptive or similar statutory or contractual rights with respect to the issuance by the Company of any securities of
the Company, including, without limitation, the Placement Securities. Except for stock options and restricted stock units approved pursuant
to Company stock-based compensation plans described in the SEC Filings or unsecured senior subordinated convertible notes described in
the SEC Filings, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any
character under which the Company is or may be obligated to issue any equity securities of any kind, except as contemplated by this Agreement.
There are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other similar agreements among the
Company and any of the securityholders of the Company relating to the securities of the Company held by them. Except as provided in the
Registration Rights Agreement, no Person has the right to (i) require the Company to register any securities of the Company under
the 1933 Act, whether on a demand basis or in connection with the registration of securities of the Company for its own account or for
the account of any other Person or (ii) prohibit the Company from filing a registration statement under the 1933 Act.
The issuance and sale of the Placement Securities
hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Investors)
and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security.
The Company does not have outstanding stockholder
purchase rights or a “poison pill” or any similar arrangement in effect giving any Person the right to purchase any equity
interest in the Company upon the occurrence of certain events.
4.4. Valid Issuance. The Shares have been
duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, fully paid and nonassessable,
and shall be free and clear of all encumbrances and restrictions (other than those created by any Investor with respect to Shares purchased
by such Investor), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws.
The Warrant Shares have been duly and validly authorized and reserved for issuance and, upon exercise of the Pre-Funded Warrants in accordance
with their terms, including the payment of any exercise price therefor, will be validly issued, fully paid and nonassessable, and shall
be free and clear of all encumbrances and restrictions (other than those created by any Investor with respect to Warrant Shares purchased
by such Investor), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws.
4.5. Consents. Subject to the accuracy
of the representations and warranties of each Investor set forth in Section 5 hereof, the execution, delivery and performance by
the Company of the Transaction Documents and the offer, issuance and sale of the Placement Securities require no consent of, action by
or in respect of, or filing with, any Person, governmental body, agency, or official other than (a) filings that have been made pursuant
to applicable state securities laws, (b) post-sale filings pursuant to applicable state and federal securities laws, (c) filings
pursuant to the rules and regulations of Nasdaq and (d) filing of the registration statement required to be filed by the Registration
Rights Agreement, each of which the Company has filed or undertakes to file within the applicable time. Subject to the accuracy of the
representations and warranties of each Investor set forth in Section 5 hereof, the Company has taken all action necessary to exempt
(i) the issuance and sale of the Placement Securities and (ii) the other transactions contemplated by the Transaction Documents
from the provisions of any stockholder rights plan or other “poison pill” arrangement, any anti-takeover, business combination
or control share law or statute binding on the Company or to which the Company or any of its assets and properties is subject that is
or could reasonably be expected to become applicable to the Investors as a result of the transactions contemplated hereby, including without
limitation, the issuance of the Placement Securities and the ownership, disposition or voting of the Shares or the Warrant Shares by the
Investors or the exercise of any right granted to the Investors pursuant to this Agreement or the other Transaction Documents.
4.6. Use of Proceeds. The net proceeds
of the sale of the Placement Securities hereunder shall be used by the Company for working capital and general corporate purposes.
4.7. No Material Adverse Change. Since
September 30, 2023, there has not been:
(i) any change in the consolidated assets, liabilities,
financial condition or operating results of the Company from that reflected in the financial statements included in the Company’s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, except for changes in the ordinary course of business
which have not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate;
(ii) any declaration or payment by the Company
of any dividend, or any authorization or payment by the Company of any distribution, on any of the capital stock of the Company, or any
redemption or repurchase by the Company of any securities of the Company;
(iii) any material damage, destruction or loss,
whether or not covered by insurance, to any assets or properties of the Company;
(iv) any waiver, not in the ordinary course
of business, by the Company of a material right or of a material debt owed to it;
(v) any satisfaction or discharge of any lien,
claim or encumbrance or payment of any obligation by the Company, except in the ordinary course of business and which is not material
to the assets, properties, financial condition, operating results or business of the Company (as such business is presently conducted);
(vi) any change or amendment to the Company’s
Certificate of Incorporation or Bylaws, or material change to any material contract or arrangement by which the Company is bound or to
which any of its assets or properties is subject;
(vii) any material labor difficulties or, to
the Company’s Knowledge, labor union organizing activities with respect to employees of the Company;
(viii) any material transaction entered into
by the Company other than in the ordinary course of business;
(ix) the loss of the services of any executive
officer (as defined in Rule 405 under the 1933 Act); or
(x) any other event or condition that has had
or would reasonably be expected to have a Material Adverse Effect.
4.8. SEC Filings. The Company has filed
all reports, schedules, forms, statements and other documents required to be filed by the Company under the 1933 Act and the 1934 Act,
including pursuant to Section 13(a) or 15(d) thereof, for the one-year period preceding the date hereof (collectively,
the “SEC Filings”). The Company meets the requirements for use of Form S-3 under the 1933 Act. At the time of
filing thereof, the SEC Filings complied as to form in all material respects with the requirements of the 1933 Act or the 1934 Act, as
applicable, and the rules and regulations of the SEC thereunder.
4.9. No Conflict, Breach, Violation or Default.
The execution, delivery and performance of the Transaction Documents by the Company and the issuance and sale of the Placement Securities
in accordance with the provisions thereof will not, except (solely in the case of clauses (i)(b) and (ii)) for such violations, conflicts
or defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (i) conflict
with or result in a breach or violation of (a) any of the terms and provisions of, or constitute a default under, the Company’s
Certificate of Incorporation or the Company’s Bylaws, both as in effect on the date hereof (true and complete copies of which have
been made available to the Investors through the Electronic Data Gathering, Analysis, and Retrieval system (the “EDGAR system”)),
or (b) assuming the accuracy of the representations and warranties in Section 5, any applicable statute, rule, regulation or
order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company or its subsidiaries,
or any of their assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time
or both would become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon any of the properties
or assets of the Company or its subsidiaries or give to others any rights of termination, amendment, acceleration or cancellation (with
or without notice, lapse of time or both) of, any Material Contract. This Section 4.9 does not relate to matters with respect to
tax status, which are the subject of Section 4.10, employee relations and labor matters, which are the subject of Section 4.13,
intellectual property matters, which are the subject of Section 4.14, or environmental matters, which are the subject of Section 4.15.
4.10. Tax Matters. The Company and its
subsidiaries have timely prepared and filed all material tax returns required to have been filed by them with all appropriate governmental
agencies and timely paid all material taxes shown thereon or otherwise owed by them. There are no material unpaid assessments against
the Company nor, to the Company’s Knowledge, any audits by any federal, state or local taxing authority. All material taxes that
the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper governmental
entity or third party when due. There are no tax liens pending or, to the Company’s Knowledge, threatened against the Company or
any of its assets or property. With the exception of agreements or other arrangements that are not primarily related to taxes entered
into in the ordinary course of business, there are no outstanding tax sharing agreements or other such arrangements between the Company
and any other corporation or entity (other than a subsidiary of the Company). The Company is classified as a Subchapter C corporation
for U.S. federal tax purposes.
4.11. Title to Properties. The Company
and its subsidiaries have good and marketable title to all real properties and all other material properties and assets owned by them,
in each case free from liens, encumbrances and defects, except such as would not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect; and the Company and its subsidiaries hold any leased real or personal property under valid and enforceable
leases with no exceptions, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect.
4.12. Certificates, Authorities and Permits.
The Company possesses adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to
conduct the business now operated by it, except where failure to so possess would not reasonably be expected, individually or in the aggregate,
to result in a Material Adverse Effect. The Company has not received any written notice of proceedings relating to the revocation or modification
of any such certificate, authority or permit that would reasonably be expected to have a Material Adverse Effect, individually or in the
aggregate, on the Company.
4.13. Labor Matters.
(a) The Company is not party to or bound
by any collective bargaining agreements or other agreements with labor organizations. To the Company’s Knowledge, the Company has
not violated in any material respect any laws, regulations, orders or contract terms affecting the collective bargaining rights of employees
or labor organizations, or any laws, regulations or orders affecting employment discrimination, equal opportunity employment, or employees’
health, safety, welfare, wages and hours.
(b) No material labor dispute with the employees
of the Company, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the
Company’s Knowledge, is threatened or imminent.
4.14. Intellectual Property. The Company
and its subsidiaries own, possess, license or have other rights to use, all patents, patent applications, trade and service marks, trade
and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, know-how and other intellectual
property (collectively, the “Intellectual Property”) necessary for the conduct of the Company’s business in all
material respects as now conducted or as proposed in the SEC Filings to be conducted; and (a) there are no rights of third parties
to any such Intellectual Property, including no liens, security interests or other encumbrances; (b) to the Company’s Knowledge,
there is no material infringement by third parties of any such Intellectual Property; (c) there is no pending or, to the Company’s
Knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s rights in or to any such Intellectual
Property; (d) such Intellectual Property that is described in the SEC Filings has not been adjudged by a court of competent jurisdiction
invalid or unenforceable, in whole or in part; (e) there is no pending or, to the Company’s Knowledge, threatened action, suit,
proceeding or claim by others challenging the validity or scope of any such Intellectual Property that is owned or licensed by the Company,
including interferences, oppositions, reexaminations or government proceedings; (f) there is no pending or, to the Company’s
Knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates, or otherwise violates any
patent, trademark, copyright, trade secret or other proprietary rights of others; and (g) to the Company’s Knowledge, each
Company employee involved with the development of Intellectual Property has entered into an invention assignment agreement with the Company.
4.15. Environmental Matters. The Company
is not in violation of any statute, rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign,
relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment
or human exposure to hazardous or toxic substances (collectively, “Environmental Laws”), has not released any hazardous
substances regulated by Environmental Laws onto any real property that it owns or operates and has not received any written notice or
claim it is liable for any off-site disposal or contamination pursuant to any Environmental Laws, which violation, release, notice, claim,
or liability would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and to the Company’s
Knowledge, there is no pending or threatened investigation that would reasonably be expected to lead to such a claim.
4.16. Legal Proceedings. There are no legal,
governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or its subsidiaries are or may reasonably
be expected to become a party or to which any property of the Company or its subsidiaries are or may reasonably be expected to become
the subject that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.
4.17. Financial Statements. The financial
statements included in each SEC Filing comply in all material respects with applicable accounting requirements and the rules and
regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement)
and present fairly, in all material respects, the consolidated financial position of the Company as of the dates shown and its consolidated
results of operations and cash flows for the periods shown, subject in the case of unaudited financial statements to normal, immaterial
year-end audit adjustments, and such consolidated financial statements have been prepared in conformity with United States generally accepted
accounting principles applied on a consistent basis during the periods involved (“GAAP”) (except as may be disclosed
therein or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP, and,
in the case of quarterly financial statements, except as permitted by Form 10-Q under the 1934 Act). Except as set forth in the financial
statements of the Company included in the SEC Filings filed prior to the date hereof, the Company has not incurred any liabilities, contingent
or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since
the date of such financial statements, none of which, individually or in the aggregate, have had or would reasonably be expected to have
a Material Adverse Effect.
4.18. Insurance Coverage. The Company maintains
in full force and effect insurance coverage that is customary for comparably situated companies for the business being conducted and properties
owned or leased by the Company, and the Company reasonably believes such insurance coverage to be adequate against all liabilities, claims
and risks against which it is customary for comparably situated companies to insure.
4.19. Compliance with Nasdaq Continued Listing
Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending
or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and
the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the
Common Stock from Nasdaq.
4.20. Brokers and Finders. Other than the
Placement Agent, no Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest
or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement
or understanding entered into by or on behalf of the Company. No Investor shall have any obligation with respect to any fees, or with
respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section 4.20
that may be due in connection with the transactions contemplated by this Agreement or the other Transaction Documents.
4.21. No Directed Selling Efforts or General
Solicitation. Neither the Company nor any Person acting on its behalf has conducted any general solicitation or general advertising
(as those terms are used in Regulation D) in connection with the offer or sale of any of the Placement Securities.
4.22. No Integrated Offering. Neither the
Company nor its subsidiaries nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company
security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company
on Section 4(a)(2) for the exemption from registration for the transactions contemplated hereby or would require registration
of the Placement Securities under the 1933 Act.
4.23. Private Placement. Assuming the accuracy
of the representations and warranties of the Investors set forth in Section 5, the offer and sale of the Placement Securities to
the Investors as contemplated hereby is exempt from the registration requirements of the 1933 Act. The issuance and sale of the Placement
Securities does not contravene the rules and regulations of Nasdaq.
4.24. Questionable Payments. Neither the
Company nor its subsidiaries nor, to the Company’s Knowledge, any of their current or former directors, officers, employees, agents
or other Persons acting on behalf of the Company or its subsidiaries, has on behalf of the Company or its subsidiaries in connection with
their business: (a) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating
to political activity; (b) made any direct or indirect unlawful payments to any governmental officials or employees from corporate
funds; (c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets which is in violation of
law; (d) made any false or fictitious entries on the books and records of the Company; or (e) made any unlawful bribe, rebate,
payoff, influence payment, kickback or other unlawful payment of any nature.
4.25. Transactions with Affiliates. None
of the executive officers or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is presently
a party to any transaction with the Company (other than as holders of stock options, restricted stock units, warrants and/or restricted
stock, and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the
furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from
any officer, director or such employee or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee or partner.
4.26. Internal Controls. The Company has
established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the 1934 Act), which are
designed to ensure that material information relating to the Company, including its subsidiaries, is made known to the Company’s
principal executive officer and its principal financial officer by others within those entities. Since the end of the Company’s
most recent audited fiscal year, there have been no material weaknesses in the Company’s internal control over financial reporting
(whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected,
or would reasonably be expected to materially affect, the Company’s internal control over financial reporting. The Company is not
aware of any change in its internal controls over financial reporting that has occurred during its most recent fiscal quarter that has
materially affected, or would reasonably be expected to materially affect, the Company’s internal control over financial reporting.
4.27. Disclosures. Neither the Company
nor any Person acting on its behalf has provided the Investors or their agents or counsel with any information that constitutes or would
reasonably be expected to constitute material non-public information concerning the Company or its subsidiaries, other than (A) with
respect to the transactions contemplated hereby, which will be disclosed in the Press Release (as defined below) and (B) as set forth
on the Disclosure Schedule. The SEC Filings do not contain any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading. The Company
understands and confirms that the Investors will rely on the foregoing representations in effecting transactions in securities of the
Company.
4.28. Required Filings. Except for (A) the
transactions contemplated by this Agreement, including the acquisition of the Placement Securities contemplated hereby and (B) as
set forth on the Disclosure Schedule, no event or circumstance has occurred or information exists with respect to the Company or its business,
properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement
by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the SEC Filings are being incorporated
by reference into an effective registration statement filed by the Company under the 1933 Act).
4.29. Investment Company. The Company is
not required to be registered as, and immediately following the Closing will not be required to register as, an “investment company”
within the meaning of the Investment Company Act of 1940, as amended.
4.30. Preclinical and Clinical Trials.
The studies, tests and preclinical and clinical trials conducted by or on behalf of the Company that are described in the SEC Filings
were and, if still pending, are being conducted, and in the case of those conducted on behalf of the Company, to the Company’s Knowledge,
in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific
standards and all applicable laws and regulations, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and
regulations promulgated thereunder; except as set forth in the Disclosure Schedule, the descriptions of the results of such studies, tests
and trials contained in the SEC Filings are accurate and complete in all material respects and fairly present the data derived from such
studies, tests and trials; the Company is not aware of any studies, tests or trials, the results of which the Company believes materially
contradict the study, test, or trial results described in the SEC Filings when viewed in the context in which such results are described
and the clinical state of development; and the Company has not received any notices or correspondence from the U.S. Food and Drug Administration
or any other federal, state, local or foreign governmental or regulatory authority requiring the termination, suspension or material modification
of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company.
4.31. Manipulation of Price. The Company
has not taken, and, to the Company’s Knowledge, no Person acting on its behalf has taken, directly or indirectly, any action designed
to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of any of the Securities.
4.32. Anti-Bribery and Anti-Money Laundering
Laws. Each of the Company, its subsidiaries and any of their respective officers, directors, supervisors, managers, agents, or employees
are and have at all times been in compliance with and its participation in the offering will not violate: (A) anti-bribery laws,
including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or
regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions,
signed December 17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any
other law, rule or regulation of similar purposes and scope or (B) anti-money laundering laws, including, but not limited to,
applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including,
without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering
principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of
which the United States is a member and with which designation the United States representative to the group or organization continues
to concur, all as amended, and any Executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any
orders or licenses issued thereunder.
4.33. No Additional Agreements. The Company
has no other agreements or understandings (including, without limitation, side letters) with any Investor to purchase Placement Securities
on terms more favorable to such Investor than as set forth herein.
4.34. Shell Company Status. The Company
is not, and has never been, an issuer identified in Rule 144(i)(1).
5. Representations and Warranties of the Investors.
Each of the Investors hereby severally, and not jointly, represents and warrants to the Company that:
5.1. Organization and Existence. Such Investor
is a duly incorporated or organized and validly existing corporation, limited partnership, limited liability company or other legal entity,
has all requisite corporate, partnership or limited liability company power and authority to enter into and consummate the transactions
contemplated by the Transaction Documents and to carry out its obligations hereunder and thereunder, and to invest in the Securities pursuant
to this Agreement, and is in good standing under the laws of the jurisdiction of its incorporation or organization.
5.2. Authorization. The execution, delivery
and performance by such Investor of the Transaction Documents to which such Investor is a party have been duly authorized and each has
been duly executed and when delivered will constitute the valid and legally binding obligation of such Investor, enforceable against such
Investor in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and similar laws of general applicability, relating to or affecting creditors’ rights generally, and general principles of equity.
5.3. Purchase Entirely for Own Account.
The Securities to be received by such Investor hereunder will be acquired for such Investor’s own account, not as nominee or agent,
for the purpose of investment and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and
such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the
1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose of all or any part of such
Securities in compliance with applicable federal and state securities laws. The Placement Securities are being purchased by such Investor
in the ordinary course of its business. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold
the Securities for any period of time. Such Investor is not a broker-dealer registered with the SEC under the 1934 Act or an entity engaged
in a business that would require it to be so registered.
5.4. Investment Experience. Such Investor
acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience
in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby.
5.5. Disclosure of Information. Such Investor
has had an opportunity to receive, review and understand all information related to the Company requested by it and to ask questions of
and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities,
and has conducted and completed its own independent due diligence. Such Investor acknowledges that copies of the SEC Filings are available
on the EDGAR system. Based on the information such Investor has deemed appropriate, and without reliance upon the Placement Agent or its
Affiliates, it has independently made its own analysis and decision to enter into the Transaction Documents. Such Investor is relying
exclusively on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the
execution, delivery and performance of the Transaction Documents, the Securities and the business, condition (financial and otherwise),
management, operations, properties and prospects of the Company, including but not limited to all business, legal, regulatory, accounting,
credit and tax matters. Such Investor has not relied on any advice furnished by or on behalf of the Placement Agent or its Affiliates
in connection with the transactions contemplated hereby. Neither such inquiries nor any other due diligence investigation conducted by
such Investor shall modify, limit or otherwise affect such Investor’s right to rely on the Company’s representations and warranties
contained in this Agreement.
5.6. Restricted Securities. Such Investor
understands that the Securities are characterized as “restricted securities” under the U.S. federal securities laws inasmuch
as they are being acquired from the Company in a transaction not involving a public offering and have not been registered under the 1933
Act or any state securities law in reliance on the availability of an exemption from such registration and that under such laws and applicable
regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances.
5.7. Legends. It is understood that, except
as provided below, certificates or book-entry records evidencing the Securities may bear the following or any similar legend:
(a) “The securities represented hereby
and the securities issuable upon exercise of these securities have not been registered with the Securities and Exchange Commission or
the securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and,
accordingly, may not be transferred unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933,
as amended, (ii) such securities may be sold pursuant to Rule 144, (iii) the Company has received an opinion of counsel
reasonably satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933, as amended,
or (iv) the securities are transferred without consideration to an affiliate of such holder or a custodial nominee (which for the
avoidance of doubt shall require neither consent nor the delivery of an opinion).”
(b) If required by the authorities of any
state in connection with the issuance or sale of the Securities, the legend required by such state authority.
5.8. Accredited Investor. Such Investor
is an institutional “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3) or (a)(7) under the
1933 Act or a “qualified institutional buyer” within the meaning of Rule 144A under the 1933 Act. Such investor is a
sophisticated “institutional account” as defined in FINRA Rule 4512(c), with sufficient knowledge and experience in investing
in private placement transactions to properly evaluate the risks and merits of its purchase of the Securities. Such Investor has determined
based on its own independent review, analysis and such professional advice as it deems appropriate that its purchase of the Securities
and participation in the transactions contemplated by the Transaction Documents (i) are fully consistent with its financial needs,
objectives and condition, (ii) comply and are fully consistent with all investment policies, guidelines and other restrictions applicable
to such Investor, (iii) have been duly authorized and approved by all necessary action, (iv) do not and will not violate or
constitute a default under such Investor’s charter, bylaws or other constituent document or under any law, rule, regulation, agreement
or other obligation by which such Investor is bound and (v) are a fit, proper and suitable investment for such Investor, notwithstanding
the substantial risks inherent in investing in or holding the Securities.
5.9 Placement Agent. Such Investor hereby
acknowledges and agrees that (a) the Placement Agent is acting solely as placement agent in connection with the execution, delivery
and performance of the Transaction Documents and is not acting as an underwriter, initial purchaser, dealer or in any other such capacity
and is not and shall not be construed as a fiduciary for such Investor, the Company or any other person or entity in connection with the
execution, delivery and performance of the Transaction Documents, (b) it is not relying upon, and has not relied upon, any statement,
representation or warranty made by the Placement Agent, any of its affiliates or any of its control persons, officers, directors and employees,
in making its investment or decision to invest in the Company, (c) the Placement Agent has not made and will not make any representation
or warranty, whether express or implied, of any kind or character, and has not provided any advice or recommendation in connection with
the execution, delivery and performance of the Transaction Documents, (d) the Placement Agent will not have any responsibility with
respect to (i) any representations, warranties or agreements made by any person or entity under or in connection with the execution,
delivery and performance of the Transaction Documents, or the execution, legality, validity or enforceability (with respect to any person)
thereof, or (ii) the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning
the Company, and (e) the Placement Agent will not have any liability or obligation (including without limitation, for or with respect
to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such
Investor, the Company or any other person or entity), whether in contract, tort or otherwise, to such Investor, or to any person claiming
through it, in respect of any action heretofore or hereafter taken or omitted to be taken by any of them in connection with any Investor’s
purchase of the Placement Securities or the execution, delivery and performance of the Transaction Documents.
5.10. No General Solicitation. Such Investor
did not learn of the investment in the Securities as a result of any general or public solicitation or general advertising, or publicly
disseminated advertisements or sales literature, including (a) any advertisement, article, notice or other communication published
in any newspaper, magazine, website, or similar media, or broadcast over television or radio, or (b) any seminar or meeting to which
such Investor was invited by any of the foregoing means of communications.
5.11. Brokers and Finders. No Person will
have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the
Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into
by or on behalf of such Investor.
5.12. Short Sales and Confidentiality Prior
to the Date Hereof. Other than consummating the transactions contemplated hereunder, such Investor has not, nor has any Person acting
on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases or sales, including Short
Sales, of the securities of the Company during the period commencing as of the time that such Investor was first contacted by the Company,
the Placement Agent or any other Person regarding the transactions contemplated hereby and ending immediately prior to the date hereof.
Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers
manage separate portions of such Investor’s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Investor’s assets, the representation set forth above shall only
apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities
covered by this Agreement. Other than to other Persons party to this Agreement and other than to such Person’s outside attorney,
accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of
the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by
law, such Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the
existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available
shares to borrow in order to effect Short Sales or similar transactions in the future.
5.13. No Government Recommendation or Approval.
Such Investor understands that no United States federal or state agency, or similar agency of any other country, has reviewed, approved,
passed upon, or made any recommendation or endorsement of the Company or the purchase of the Securities.
5.14. No Intent to Effect a Change of Control.
Such Investor has no present intent to effect a “change of control” of the Company as such term is understood under the rules promulgated
pursuant to Section 13(d) of the 1934 Act.
5.15. Residency. Such Investor’s
office in which its investment decision with respect to the Securities was made is located at the address immediately below such Investor’s
name on its signature page hereto, except as otherwise communicated in writing by such Investor to the Company.
5.16. No Conflicts. The execution, delivery
and performance by such Investor of the Transaction Documents and the consummation by such Investor of the transactions contemplated hereby
and thereby will not (i) result in a violation of the organizational documents of such Investor or (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Investor is a party, or (iii) result
in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such
Investor, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would
not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Investor to perform
its obligations hereunder.
6. Conditions to Closing.
6.1. Conditions to the Investors’ Obligations.
The obligation of each Investor to purchase Placement Securities at the Closing is subject to the fulfillment to such Investor’s
satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to itself
only):
(a) The representations and warranties made
by the Company in Section 4 hereof shall be true and correct in all material respects, except for those representations and warranties
qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, as of the date hereof and as of
the Closing Date, as though made on and as of such date, except to the extent any such representation or warranty expressly speaks as
of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier
date, except for those representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct
in all respects as of such earlier date. The Company shall have performed in all material respects all obligations and covenants herein
required to be performed by it on or prior to the Closing Date.
(b) The Company shall have obtained any and
all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the Placement Securities
and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect.
(c) The Company shall have executed and delivered
the Registration Rights Agreement.
(d) The Company shall have filed with Nasdaq
a Listing of Additional Shares notice form for the listing of the Shares and the Warrant Shares.
(e) No judgment, writ, order, injunction,
award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any
governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority,
enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Documents.
(f) The Company shall have delivered a Certificate,
executed on behalf of the Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying
to the fulfillment of the conditions specified in subsections (a), (b), (d), (e), (i) and (j) of this Section 6.1.
(g) The Company shall have delivered a Certificate,
executed on behalf of the Company by its Secretary, dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors
of the Company approving the transactions contemplated by this Agreement, the other Transaction Documents and the issuance of the Placement
Securities, certifying the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures
and authority of persons signing the Transaction Documents and related documents on behalf of the Company.
(h) The Investors shall have received an
opinion from Wilmer Cutler Pickering Hale and Dorr LLP, the Company’s counsel, dated as of the Closing Date, in form and substance
reasonably acceptable to the Investors.
(i) There shall have been no Material Adverse
Effect with respect to the Company since the date hereof.
(j) No stop order or suspension of trading
shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock.
6.2. Conditions to Obligations of the Company.
The Company’s obligation to sell and issue the Placement Securities at the Closing is subject to the fulfillment to the satisfaction
of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company:
(a) The representations and warranties made
by the Investors in Section 5 hereof shall be true and correct in all material respects, except for those representations and warranties
qualified by materiality or material adverse effect, which shall be true and correct in all respects, as of the date hereof, and shall
be so true and correct as of the Closing Date with the same force and effect as if they had been made on and as of such date. The Investors
shall have performed in all material respects all obligations and covenants herein required to be performed by them on or prior to the
Closing Date.
(b) Each Investor shall have executed and
delivered the Registration Rights Agreement.
(c) Any Investor purchasing Placement Securities
at the Closing shall have paid in full its purchase price to the Company.
6.3. Termination of Obligations to Effect Closing;
Effects.
(a) The obligations of the Company, on the
one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:
(i) Upon the mutual written consent of the Company
and Investors that agreed to purchase a majority of the Placement Securities to be issued and sold pursuant to this Agreement;
(ii) By the Company if any of the conditions
set forth in Section 6.2 shall have become incapable of fulfillment, and shall not have been waived by the Company;
(iii) By an Investor (with respect to itself
only) if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and shall not have been waived
by such Investor; or
(iv) By either the Company or any Investor (with
respect to itself only) if the Closing has not occurred on or prior to the fifth Trading Day following the date of this Agreement;
provided, however, that, except in the case of clause (i) above,
the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties,
covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted in the circumstances
giving rise to such party’s seeking to terminate its obligation to effect the Closing.
(b) In the event of termination by the Company
or any Investor of its obligations to effect the Closing pursuant to this Section 6.3, written notice thereof shall be given to the
other Investors by the Company and the other Investors shall have the right to terminate their obligations to effect the Closing upon
written notice to the Company and the other Investors. Nothing in this Section 6.3 shall be deemed to release any party from any
liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the
right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction
Documents.
7. Covenants and Agreements of the Company.
7.1. Removal of Legends.
(a) In connection with any sale, assignment,
transfer or other disposition of the Shares or Warrant Shares by an Investor pursuant to Rule 144 or pursuant to any other exemption
under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of
this Agreement, if requested by the Investor, the Company shall request the transfer agent for the Common Stock (the “Transfer
Agent”) to remove any restrictive legends related to the book entry account holding such Shares or Warrant Shares and to make
a new, unlegended entry for such book entry shares sold or disposed of without restrictive legends within two (2) Trading Days of
any such request therefor from such Investor, provided that the Company has timely received from the Investor customary representations
and other documentation reasonably acceptable to the Company in connection therewith.
(b) Subject to receipt from the Investor
by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable to the Company and the
Transfer Agent in connection therewith, upon the earliest of such time as the Shares or Warrant Shares (i) have been registered under
the 1933 Act pursuant to an effective registration statement, (ii) have been sold pursuant to Rule 144, or (iii) are eligible
for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance with the current public information
requirements under Rule 144(c)(1) (or any successor provision), the Company shall, in accordance with the provisions of this
Section 7.1(b) and within two (2) Trading Days of any request therefor from an Investor accompanied by such customary and
reasonably acceptable documentation referred to above, (A) deliver to the Transfer Agent irrevocable instructions that the Transfer
Agent shall make a new, unlegended entry for such book entry Shares or Warrant Shares, and (B) cause its counsel to deliver to the
Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the 1933
Act if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement. Shares
or Warrant Shares subject to legend removal hereunder may be transmitted by the Transfer Agent to the Investor by crediting the account
of the Investor’s prime broker with the DTC System as directed by such Investor. The Company shall be responsible for the fees of
its Transfer Agent and all DTC fees associated with such issuance.
(c) Each Investor, severally and not jointly
with the other Investors, agrees with the Company (i) that such Investor will sell any Securities only pursuant to either the registration
requirements of the 1933 Act, including any applicable prospectus delivery requirements, or an exemption therefrom, (ii) that if
Shares or Warrant Shares are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution
set forth therein and (iii) that if, after the effective date of the registration statement covering the resale of the Shares and
Warrant Shares, such registration statement ceases to be effective and the Company has provided notice to such Investor to that effect,
such Investor will sell Shares and Warrant Shares only in compliance with an exemption from the registration requirements of the 1933
Act.
7.2. Subsequent Equity Sales.
(a) From the date hereof until the earlier
of (i) sixty (60) days after the Closing Date and (ii) the Trading Day immediately following the effective date of the registration
statement filed pursuant to the Registration Rights Agreement, without the consent of the Required Investors, the Company shall not (A) issue
shares of Common Stock or Common Stock Equivalents, (B) effect a reverse stock split, recapitalization, share consolidation, reclassification
or similar transaction affecting the outstanding Common Stock or (C) file with the SEC a registration statement under the 1933 Act
relating to any shares of Common Stock or Common Stock Equivalents, except pursuant to the terms of the Registration Rights Agreement.
Notwithstanding the foregoing, the provisions of this Section 7.2 shall not apply to (i) the issuance of the Securities hereunder,
(ii) the issuance of Common Stock or Common Stock Equivalents upon the conversion, exercise or vesting of any securities of the Company
outstanding on the date hereof (provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities or to extend the term of such
securities) or outstanding pursuant to clause (iii) or (v) below, (iii) the issuance of any Common Stock or Common Stock
Equivalents pursuant to any Company stock-based compensation plans or in accordance with Nasdaq Stock Market Rule 5635(c)(4), (iv) the
filing of a registration statement on Form S-8 under the 1933 Act to register the offer and sale of securities on an equity incentive
plan or employee stock purchase plan, (v) the issuance of any Common Stock or Common Stock Equivalents in connection with a transaction
with an unaffiliated third party that includes a bona fide commercial relationship with the Company (including any joint venture, marketing
or distribution arrangement, strategic alliance, collaboration agreement or corporate partnering, intellectual property license agreement
or acquisition agreement or other strategic transaction or debt financing transaction with the Company); provided, however, that the aggregate
number of shares of Common Stock issued pursuant to clause (v) during the restricted period shall not exceed 10% of the total number
of shares of Common Stock issued and outstanding immediately following the Closing or (vi) the offer, issuance and sale of shares
of Common Stock pursuant to our Open Market Sale AgreementSM with Jefferies LLC, provided no shares may be issued under such
agreement until the earlier of (i) thirty (30) days after the Closing Date and (ii) the Trading Day immediately following the
effective date of the registration statement filed pursuant to the Registration Rights Agreement.
(b) The Company shall not, and shall use
its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or
otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will be integrated with the offer or
sale of the Placement Securities in a manner that would require the registration under the 1933 Act of the sale of the Placement Securities
to the Investors, or that will be integrated with the offer or sale of the Placement Securities for purposes of the rules and regulations
of any trading market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder
approval is obtained before the closing of such subsequent transaction.
7.3. Fees. The Company shall be responsible
for the payment of any placement agent’s fees, financial advisory fees, or broker’s commissions (other than for Persons engaged
by any Investor) relating to or arising out of the transactions contemplated hereby, including, without limitation, any fees or commissions
payable to the Placement Agent.
7.4. Short Sales and Confidentiality After
the Date Hereof. Each Investor covenants that neither it nor any Affiliates acting on its behalf or pursuant to any understanding
with it will trade in the securities of the Company or execute any Short Sales during the period from the date hereof until the earlier
of such time as (i) both (a) the transactions contemplated by this Agreement are first publicly announced and (b) all material
information set forth in the Disclosure Schedule have been publicly disclosed by the Company or (ii) both (a) this Agreement
is terminated in full and (b) all material information set forth in the Disclosure Schedule have been publicly disclosed by the Company.
Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers
manage separate portions of such Investor’s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Investor’s assets, the covenant set forth above shall only apply
with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Placement Securities.
Each Investor covenants that until such time (i) as all material terms of the sale of the Placement Securities to the Investors pursuant
to this Agreement are publicly disclosed by the Company, such Investor and its Affiliates will maintain the confidentiality of the existence
and terms of this Agreement and (ii) as all material information set forth in the Disclosure Schedule is publicly disclosed by the
Company, such Investor and its Affiliates will maintain the confidentiality of all information included on the Disclosure Schedule, other
than, in each case, to such Person’s outside attorney, accountant, auditor or investment advisor only to the extent necessary to
permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative
tasks and services and other than as may be required by law.
7.5. Nasdaq Listing. The Company will use
commercially reasonable efforts to continue the listing and trading of its Common Stock on Nasdaq and, in accordance therewith, will use
commercially reasonable efforts to comply in all material respects with the Company’s reporting, filing and other obligations under
the bylaws or rules of such market or exchange, as applicable.
8. Survival and Indemnification.
8.1. Survival. The representations, warranties,
covenants and agreements contained in this Agreement shall survive the Closing of the transactions contemplated by this Agreement for
the applicable statute of limitations.
8.2. Indemnification. The Company agrees
to indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees, members, managers,
employees, investment advisers and agents, from and against any and all losses, claims, damages, liabilities and expenses (including without
limitation reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in
connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement
thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by
or to be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts
as they are incurred by such Person solely to the extent such amounts have been finally judicially determined not to have resulted from
such Person’s fraud or willful misconduct.
8.3. Conduct of Indemnification Proceedings. Any
person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect
to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably
satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ
separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of
such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party
shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable
judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying
party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to
employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense
of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written
notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure
to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood
that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more
than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent
of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, effect any settlement of or consent
to the entry of any judgment with respect to any pending proceeding in respect of which any indemnified party is or could have been a
party and indemnity could have been sought hereunder by such indemnified party, unless such settlement (i) includes an unconditional
release of such indemnified party from all liability in respect of or arising out of such claims or proceedings that are the subject matter
of such proceeding, (ii) imposes no liability or obligation on the indemnified party and (iii) does not include any admission
of fault, culpability, wrongdoing or malfeasance by or on behalf of the indemnified party.
9. Miscellaneous.
9.1. Successors and Assigns. This Agreement
may not be assigned by a party hereto without the prior written consent of the Company or each of the Investors, as applicable, provided,
however, that an Investor may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or to a third party
acquiring some or all of its Securities in a transaction complying with applicable securities laws without the prior written consent of
the Company or the other Investors, provided such assignee agrees in writing to be bound by the provisions hereof that apply to Investors.
The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of
the parties. Without limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share
exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of another Person,
from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the
obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person and the term “Securities”
shall be deemed to refer to the securities received by the Investors in connection with such transaction. Nothing in this Agreement, express
or implied, is intended to confer upon any party other than the parties hereto or their respective permitted successors and assigns any
rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
9.2. Counterparts. This Agreement may be
executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signatures complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have
been duly and validly delivered and be valid and effective for all purposes.
9.3. Titles and Subtitles. The titles and
subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
9.4. Notices. Unless otherwise provided,
any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described
(i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given by e-mail, then
such notice shall be deemed given when sent with no mail undeliverable or other rejection notice, (iii) if given by mail, then such
notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three days after such notice
is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier, then
such notice shall be deemed given one Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified
at the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the other
party:
If to the Company:
Ocular Therapeutix, Inc.
24 Crosby Drive
Bedford, Massachusetts 01730
Attention: Chief Financial Officer
Facsimile: [**]
Email: [**]
With a copy (which shall not constitute notice) to:
Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Attention: Stuart Falber, Esq.
Facsimile: (617) 526-5000
Email: [**]
If to the Investors:
Only to the addresses set forth on the signature
pages hereto.
9.5. Expenses. The parties hereto shall
pay their own costs and expenses in connection herewith regardless of whether the transactions contemplated hereby are consummated; it
being understood that each of the Company and each Investor has relied on the advice of its own respective counsel.
9.6. Amendments and Waivers. Prior to Closing,
no amendment or waiver of any provision of this Agreement will be effective with respect to any party unless made in writing and signed
by a duly authorized representative of such party. Following the Closing, any term of this Agreement may be amended and the observance
of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively),
only with the written consent of the Company and the Required Investors. Notwithstanding the foregoing, this Agreement may not be amended
and the observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor
unless such amendment or waiver applies to all Investors in the same fashion. Any amendment or waiver effected in accordance with this
paragraph shall be binding upon, prior to the Closing, each Investor that signed such amendment or waiver.
9.7. Publicity.
(a) Except as set forth below, no public
release or announcement concerning the transactions contemplated hereby shall be issued by the Investors without the prior consent of
the Company and the Placement Agent, except as such release or announcement may be required by law or the applicable rules or regulations
of any securities exchange or securities market, in which case the Investors shall allow the Company and the Placement Agent reasonable
time to comment on such release or announcement in advance of such issuance. Notwithstanding the foregoing, each Investor may identify
the Company and the value of such Investor’s security holdings in the Company in accordance with applicable investment reporting
and disclosure regulations or internal policies without prior notice to or consent from the Company (including, for the avoidance of doubt,
filings pursuant to Sections 13 and 16 of the 1934 Act). The Company shall not include the name of any Investor or any Affiliate or investment
adviser of such Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any SEC Filing
to the extent such disclosure is required by SEC rules and regulations) without the prior written consent of such Investor; provided,
however, that to the extent such disclosure is required by law, including SEC rules and regulations, the Company shall promptly provide
the Investor with prior notice of such disclosure and the opportunity to review such disclosure.
(b) No later than 9:30 a.m. (Eastern
time) on the Disclosure Date, the Company shall issue a press release disclosing all material terms of the transactions contemplated by
this Agreement (the “Press Release”).
(c) No later than 9:30 a.m. (Eastern
time) on the Disclosure Date, the Company shall issue a press release and/or a Current Report on Form 8-K disclosing the material
information set forth in the Disclosure Schedule. Following 9:30 a.m. (Eastern Time) on the Disclosure Date, no Investor shall be
in possession of any material non-public information received from the Company, its subsidiaries or any of their respective officers,
directors, employees or agents (including the Placement Agent).
(d) The Company will make such other filings
and notices in the manner and time required by the SEC or Nasdaq.
9.8. Severability. Any provision of this
Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such
prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so
as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction
shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the
parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect.
9.9. Benefit of Agreement. The Placement
Agent is an intended third-party beneficiary of the representations and warranties of the Company and of each Investor set forth in Section 4
and Section 5, respectively, of this Agreement.
9.10. Entire Agreement. This Agreement,
including the signature pages, Exhibits, the other Transaction Documents and any confidentiality agreements between the Company and any
Investor constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof;
provided, however, that with respect to any conflict between this Agreement and the Registration Rights Agreement, the Registration Rights
Agreement shall govern as it relates to the registration of the resale of the Securities.
9.11. Further Assurances. The parties shall
execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry
out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.
9.12. Governing Law. This Agreement shall
be governed by, and construed in accordance with, the laws of the State of New York. Service of process in connection with any suit, action
or proceeding arising hereunder may be served on each party hereto anywhere in the world by the same methods as are specified for the
giving of notices under this Agreement.
9.13. Independent Nature of Investors’
Obligations and Rights. The obligations of each Investor under any Transaction Document are several and not joint with the obligations
of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under
any Transaction Document. The decision of each Investor to purchase Placement Securities pursuant to the Transaction Documents has been
made by such Investor independently of any other Investor. Nothing contained herein or in any Transaction Document, and no action taken
by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any
other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations
or the transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other Investor has acted as agent for
such Investor in connection with making its investment hereunder and that no Investor will be acting as agent of such Investor in connection
with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Investor shall be entitled
to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the
other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding
for such purpose. The Company acknowledges that each of the Investors has been provided with the same Transaction Documents for the purpose
of closing a transaction with multiple Investors and not because it was required or requested to do so by any Investor. It is expressly
understood and agreed that each provision contained in this Agreement is between the Company and an Investor, solely, and not between
the Company and the Investors collectively and not between and among the Investors.
9.14. Exculpation of the Placement Agent.
Each party hereto agrees for the express benefit of the Placements Agent and its Affiliates and representatives that:
(i) neither the Placement Agent nor any of
its Affiliates or any of its representatives (1) has any duties or obligations other than those specifically set forth herein or
in the engagement letter, dated February 20, 2024, between the Company and BofA Securities, Inc. (the “Engagement Letter”);
(2) shall be liable for any improper payment made in accordance with the information provided by the Company; (3) makes any
representation or warranty, or has any responsibilities as to the validity, accuracy, value or genuineness of any information, certificates
or documentation delivered by or on behalf of the Company pursuant to this Agreement or the other Transaction Documents or in connection
with any of the transactions contemplated hereby and thereby; or (4) shall be liable (x) for any action taken, suffered or omitted
by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or powers conferred upon it by
this Agreement or any Transaction Document or (y) for anything which any of them may do or refrain from doing in connection with
this Agreement or any Transaction Document, except in each case for such party’s own gross negligence, willful misconduct or bad
faith; and
(ii) the Placement Agent, its Affiliates and
its representatives shall be entitled to (1) rely on, and shall be protected in acting upon, any certificate, instrument, notice,
letter or any other document or security delivered to any of them by or on behalf of the Company, and (2) be indemnified by the Company
for acting as the Placement Agent hereunder pursuant to the indemnification provisions set forth in the Engagement Letter.
9.15. Cumulative Remedies. The remedies
provided herein are cumulative and not exclusive of any remedies provided by law.
[remainder of page intentionally left blank]
IN WITNESS WHEREOF, the parties have executed
this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.
COMPANY: |
OCULAR
THERAPEUTIX, INC. |
|
|
|
|
By: |
/s/ Donald Notman |
|
|
Name:
Donald Notman |
|
|
Title:
Chief Financial Officer |
INVESTOR: |
[________________________] |
|
|
|
By: |
|
|
|
Name: |
|
|
Title: |
EXHIBIT A
Schedule of Investors
Investor Name | |
Number of
Shares to be Purchased | |
Number of Warrant Shares Underlying Pre-Funded Warrant Purchased | |
Aggregate Purchase Price of Placement Securities |
Avoro Life Sciences Fund LLC | |
6,648,936 | |
4,654,874 | |
$ | 84,999,996.33 |
Venrock Opportunities Fund, L.P. | |
1,994,681 | |
1,994,946 | |
$ | 30,000,000.09 |
Venrock Healthcare Capital Partners EG, L.P. | |
2,274,834 | |
2,275,136 | |
$ | 34,213,499.26 |
Venrock Healthcare Capital Partners III, L.P. | |
651,961 | |
652,048 | |
$ | 9,805,495.63 |
VHCP Co-Investment Holdings III, LLC | |
65,226 | |
65,235 | |
$ | 981,001.49 |
TCG Crossover Fund II, L.P. | |
5,319,148 | |
| |
$ | 39,999,992.96 |
Deep Track Biotechnology Master Fund, Ltd. | |
3,490,691 | |
1,163,718 | |
$ | 34,999,991.96 |
Perceptive Life Sciences Master Fund, Ltd. | |
3,324,468 | |
| |
$ | 24,999,999.36 |
Biomedical Value Fund, L.P. | |
954,255 | |
| |
$ | 7,175,997.60 |
Biomedical Offshore Value Fund, Ltd. | |
656,915 | |
| |
$ | 4,940,000.80 |
Cheyne Select Master Fund ICAV – Cheyne Global Equity Fund | |
117,553 | |
| |
$ | 883,998.56 |
Logos Global Master Fund LP | |
1,961,436 | |
| |
$ | 14,749,998.72 |
Citadel CEMF Investments Ltd. | |
1,994,680 | |
| |
$ | 14,999,993.60 |
Cap 1 LLC | |
558,510 | |
| |
$ | 4,199,995.20 |
East River Partners Ltd | |
372,341 | |
| |
$ | 2,800,004.32 |
Acuta Capital Fund, LP | |
1,090,425 | |
| |
$ | 8,199,996.00 |
Acuta Opportunity Fund, LP | |
239,362 | |
| |
$ | 1,800,002.24 |
Opaleye, L.P. | |
698,138 | |
| |
$ | 5,249,997.76 |
TOTAL | |
32,413,560 | |
10,805,957 | |
$ | 324,999,961.88 |
Exhibit 10.2
Execution Version
REGISTRATION
RIGHTS AGREEMENT
This Registration
Rights Agreement (this “Agreement”) is made and entered into as of February 21, 2024, by and among Ocular
Therapeutix, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain
Securities Purchase Agreement by and among the Company and the Investors, dated as of the date hereof (the “Purchase Agreement”).
Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
The parties hereby agree as follows:
1. Definitions.
As used in this Agreement, the following terms
shall have the following meanings:
“Agreement” has the meaning
set forth in the first paragraph.
“Allowed Delay” has the meaning
set forth in Section 2(c)(ii).
“Availability Date” has the
meaning set forth in Section 3(i).
“Blackout Period” has the meaning
set forth in Section 2(d)(ii).
“Company” has the meaning set
forth in the first paragraph.
“Cut Back Shares” has the meaning
set forth in Section 2(e).
“Effectiveness Liquidated Damages”
has the meaning set forth in Section 2(d)(ii).
“Effectiveness Period” has
the meaning set forth in Section 3(a).
“Filing Deadline” has the meaning
set forth in Section 2(a)(i).
“Inspectors” has the meaning
set forth in Section 4.
“Investors” means the Investors
identified in the Purchase Agreement and any Affiliate or permitted transferee of any Investor who is a subsequent holder of Registrable
Securities.
“Liquidated Damages” has the
meaning set forth in Section 2(d)(ii).
“Maintenance Failure” has the
meaning set forth in Section 2(d)(ii).
“Prospectus” means (i) the
prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with respect to the terms
of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements
to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus, and (ii) any
“free writing prospectus” as defined in Rule 405 under the 1933 Act.
“Purchase Agreement” has the
meaning set forth in the first paragraph.
“Qualification Date” has the
meaning set forth in Section 2(a)(ii).
“Qualification Deadline” has
the meaning set forth in Section 2(a)(ii).
“Records” has the meaning set
forth in Section 4.
“Register,” “registered”
and “registration” refer to a registration made by preparing and filing a Registration Statement or similar document
in compliance with the 1933 Act, and the declaration or ordering of effectiveness of such Registration Statement or document.
“Registrable Securities” means
(i) the Shares, (ii) the Warrant Shares and (iii) any other securities issued or issuable with respect to or in exchange
for Shares or Warrant Shares, whether by merger, charter amendment or otherwise; provided, that a security shall cease to be a Registrable
Security upon the earliest of: (A) sale pursuant to a Registration Statement or Rule 144 under the 1933 Act, (B) such
security becoming eligible for sale without restriction by the Investor holding such security pursuant to Rule 144, including without
any manner of sale or volume limitations, and without the requirement to be in compliance with Rule 144(c)(1) (or any successor
thereto) promulgated under the 1933 Act, or (C) five years after the Closing Date.
“Registration Liquidated Damages”
has the meaning set forth in Section 2(d)(i).
“Registration Statement” means
any registration statement of the Company under the 1933 Act that covers the resale of any of the Registrable Securities pursuant to
the provisions of this Agreement, amendments and supplements to such Registration Statement, including post-effective amendments, all
exhibits and all material incorporated by reference in such Registration Statement.
“Required Investors” means
the Investors holding a majority of the Registrable Securities outstanding from time to time.
“Restriction Termination Date”
has the meaning set forth in Section 2(e).
“SEC” means the U.S. Securities
and Exchange Commission.
“SEC Restrictions” has the
meaning set forth in Section 2(e).
“Shelf Registration Statement”
has the meaning set forth in Section 2(a)(ii).
2. Registration.
(a) Registration
Statements.
(i) Promptly
following the Closing Date but no later than thirty (30) days after the Closing Date (the “Filing Deadline”), the
Company shall prepare and file with the SEC one Registration Statement covering the resale of all of the Registrable Securities. Subject
to any SEC comments, such Registration Statement shall include the plan of distribution, substantially in the form and substance attached
hereto as Exhibit A; provided, however, that no Investor shall be named as an “underwriter” in such Registration
Statement without the Investor’s prior written consent. Such Registration Statement also shall cover, to the extent allowable under
the 1933 Act and the rules promulgated thereunder (including Rule 416), such indeterminate number of additional shares of Common
Stock resulting from stock splits, stock dividends or similar transactions with respect to the Registrable Securities. Such Registration
Statement shall not include any shares of Common Stock or other securities for the account of any other holder of securities of the Company
without the prior written consent of the Required Investors. Such Registration Statement (and each amendment or supplement thereto, and
each request for acceleration of effectiveness thereof) shall be provided in accordance with Section 3(c) to the Investors
prior to its filing or other submission.
(ii) The
Registration Statement referred to in Section 2(a)(i) shall be on Form S-3. In the event that Form S-3 is not available
for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable
Securities on such other form as is available to the Company and (ii) so long as Registrable Securities remain outstanding, promptly
following the date (the “Qualification Date”) upon which the Company becomes eligible to use a registration statement
on Form S-3 to register the Registrable Securities for resale, but in no event more than thirty (30) days after the Qualification
Date (the “Qualification Deadline”), file a registration statement on Form S-3 covering the Registrable Securities
(or a post-effective amendment on Form S-3 to a registration statement on Form S-1) (a “Shelf Registration Statement”)
and use commercially reasonable efforts to cause such Shelf Registration Statement to be declared effective as promptly as practicable
thereafter; provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as
a Shelf Registration Statement covering the Registrable Securities has been declared effective by the SEC.
(b) Expenses.
The Company will pay all expenses associated with each Registration Statement, including filing and printing fees, the Company’s
counsel and accounting fees and expenses, costs associated with clearing the Registrable Securities for sale under applicable state securities
laws and listing fees, but excluding discounts, commissions, fees of underwriters, selling brokers, dealer managers or similar securities
industry professionals with respect to the Registrable Securities being sold.
(c) Effectiveness.
(i) The
Company shall use commercially reasonable efforts to have each Registration Statement declared effective, if not automatically effective
upon filing, as soon as reasonably practicable after such Registration Statement has been filed with the SEC. The Company shall notify
the Investors by facsimile or e-mail as promptly as practicable, and in any event, within twenty-four (24) hours, after any Registration
Statement becomes or is declared effective and shall provide the Investors with copies of any related Prospectus to be used in connection
with the sale or other disposition of the securities covered thereby.
(ii) For
not more than thirty (30) consecutive days or for a total of not more than ninety (90) days in any twelve (12) month period, the Company
may suspend the use of any Prospectus included in any Registration Statement contemplated by this Section in the event that the
Company determines in good faith that such suspension is necessary to (A) delay the disclosure of material nonpublic information
concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of
the Company or (B) amend or supplement the affected Registration Statement or the related Prospectus so that such Registration Statement
or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances under which they were made,
not misleading (an “Allowed Delay”); provided, that the Company shall promptly (a) notify each Investor in writing
of the commencement of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to such Investor any
material nonpublic information giving rise to an Allowed Delay, (b) advise the Investors in writing to cease all sales under such
Registration Statement until the end of the Allowed Delay and (c) use commercially reasonable efforts to terminate an Allowed Delay
as promptly as practicable.
(d) Effect
of Failure to File and Obtain and Maintain Effectiveness of Registration Statement.
(i) If
a Registration Statement covering the Registrable Securities is not filed with the SEC on or prior to the Filing Deadline, the Company
will make pro rata payments to each Investor then holding Registrable Securities, as liquidated damages and not as a penalty (the “Registration
Liquidated Damages”), in an amount equal to one percent (1.0%) of the aggregate amount invested by such Investor for the initial
day of failure to file such Registration Statement by the Filing Deadline and for each subsequent 30-day period (pro rata for any portion
thereof) thereafter for which no such Registration Statement is filed with respect to the Registrable Securities. Such payments shall
be made to each Investor then holding Registrable Securities in cash no later than ten (10) Business Days after the end of the date
of the initial failure to file such Registration Statement by the Filing Deadline and each subsequent 30-day period (pro rata for any
portion thereof) until such Registration Statement is filed with respect to the Registrable Securities. Interest shall accrue at the
rate of one percent (1.0%) per month on any such liquidated damages payments that shall not be paid by the applicable payment date until
such amount is paid in full.
(ii) If
(A) a Registration Statement covering the Registrable Securities is not automatically effective upon filing with the SEC or not
declared effective by the SEC prior to the earlier of (i) five (5) Business Days after the SEC informs the Company that no
review of such Registration Statement will be made or that the SEC has no further comments on such Registration Statement or (ii) the
60th day after the Closing Date (or the 90th day after the Closing Date if the SEC reviews such Registration Statement),
or (B) after a Registration Statement has been declared effective by the SEC or otherwise becomes effective, sales cannot be made
pursuant to such Registration Statement for any reason (including, without limitation, by reason of a stop order or the Company’s
failure to update such Registration Statement), but excluding any Allowed Delay or the inability of any Investor to sell the Registrable
Securities covered thereby due to market conditions (each of (A) and (B), a “Maintenance Failure”), then the
Company will make pro rata payments to each Investor then holding Registrable Securities, as liquidated damages and not as a penalty
(the “Effectiveness Liquidated Damages” and together with the Registration Liquidated Damages, the “Liquidated
Damages”), in an amount equal to one percent (1.0%) of the aggregate amount invested by such Investor for the Registrable Securities
then held by such Investor for the initial day of a Maintenance Failure and for each 30-day period (pro rata for any portion thereof)
thereafter until the Maintenance Failure is cured (each, a “Blackout Period”). The Effectiveness Liquidated Damages
shall be paid monthly within ten (10) Business Days of the end of the date of such Maintenance Failure and each subsequent 30-day
period (pro rata for any portion thereof), as applicable. Such payments shall be made to each Investor then holding Registrable Securities
in cash. Interest shall accrue at the rate of one percent (1.0%) per month on any such liquidated damages payments that shall not be
paid by the applicable payment date until such amount is paid in full.
(iii) The
parties agree that (1) notwithstanding anything to the contrary herein or in the Purchase Agreement, no Liquidated Damages shall
be payable with respect to any period after the expiration of the Effectiveness Period (it being understood that this sentence shall
not relieve the Company of any Liquidated Damages accruing prior to the expiration of the Effectiveness Period), and in no event shall
the aggregate amount of Liquidated Damages payable to an Investor exceed, in the aggregate, six percent (6.0%) of the aggregate purchase
price paid by such Investor pursuant to the Purchase Agreement and (2) except with respect to (A) the initial day of failure
to file a Registration Statement by the Filing Deadline and (B) the initial day of any Maintenance Failure, in no event shall the
Company be liable in any thirty (30) day period for Liquidated Damages under this Agreement in excess of one percent (1.0%) of the aggregate
purchase price paid by the Investors pursuant to the Purchase Agreement.
(iv) Notwithstanding
the foregoing, the Company and the Investors agree that the Company will not be liable for any Liquidated Damages under this Section 2(d) with
respect to any Registrable Securities prior to their issuance. The Liquidated Damages described in this Section 2(d) shall
constitute the Investors’ exclusive monetary remedy for any failure to meet the Filing Deadline and for any Maintenance Failure,
but shall not affect the right of the Investors to injunctive relief.
(e) Rule 415;
Cutback. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in a Registration
Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the 1933 Act or requires
any Investor to be named as an “underwriter,” the Company shall use commercially reasonable efforts to advocate before the
SEC its reasonable position that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering
“by or on behalf of the issuer” as defined in Rule 415 and that none of the Investors is an “underwriter.”
The Investors shall have the right to select one legal counsel to review and oversee any registration or matters pursuant to this Section 2(e),
including participation in any meetings or discussions with the SEC regarding the SEC’s position and to comment on any written
submission made to the SEC with respect thereto, which counsel shall be designated by the holders of a majority of the Registrable Securities.
In the event that, despite the Company’s commercially reasonable efforts and compliance with the terms of this Section 2(e),
the SEC does not alter its position, the Company shall (i) remove from such Registration Statement such portion of the Registrable
Securities (the “Cut Back Shares”) and/or (ii) agree to such restrictions and limitations on the registration
and resale of the Registrable Securities as the SEC may require to assure the Company’s compliance with the requirements of Rule 415
(collectively, the “SEC Restrictions”); provided, however, that the Company shall not agree to name any Investor as
an “underwriter” in such Registration Statement without the prior written consent of such Investor. Any cut-back imposed
on the Investors pursuant to this Section 2(e) shall be allocated among the Investors on a pro rata basis and shall be applied
first to any of the Registrable Securities of such Investor as such Investor shall designate, unless the SEC Restrictions otherwise require
or provide or the Investors otherwise agree. No liquidated damages shall accrue as to any Cut Back Shares until such date as the Company
is able to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions applicable to such Cut Back Shares
(such date, the “Restriction Termination Date”). From and after the Restriction Termination Date applicable to any
Cut Back Shares, all of the provisions of this Section 2 (including the Company’s obligations with respect to the filing of
a Registration Statement and its obligations to use commercially reasonable efforts to have such Registration Statement declared effective
within the time periods set forth herein and the liquidated damages provisions relating thereto) shall again be applicable to such Cut
Back Shares; provided, however, that (i) the Filing Deadline and/or the Qualification Deadline, as applicable, for such Registration
Statement including such Cut Back Shares shall be ten (10) Business Days after such Restriction Termination Date, and (ii) the
date by which the Company is required to obtain effectiveness with respect to such Cut Back Shares under Section 2(c) shall
be the 90th day immediately after the Restriction Termination Date (or the 120th day if the SEC reviews such Registration
Statement).
3. Company
Obligations. The Company will (a) use commercially reasonable efforts to effect the registration of the Registrable Securities
in accordance with the terms hereof and (b) as expeditiously as possible:
(a) use
commercially reasonable efforts to cause such Registration Statement to become effective (if not automatically effective upon filing)
and to remain continuously effective for a period that will terminate upon the earlier of (i) the date on which all Registrable
Securities covered by such Registration Statement, as amended from time to time, have been sold, and (ii) the date on which all
Shares and Warrant Shares cease to be Registrable Securities (the “Effectiveness Period”);
(b) prepare
and file with the SEC such amendments and post-effective amendments to such Registration Statement and the related Prospectus as may
be necessary to keep such Registration Statement effective for the Effectiveness Period and to comply with the provisions of the 1933
Act and the 1934 Act with respect to the distribution of all of the Registrable Securities covered thereby;
(c) provide
copies to and permit each Investor to review each Registration Statement and all amendments and supplements thereto no fewer than two
(2) days prior to their filing with the SEC and to furnish reasonable comments thereon;
(d) furnish
to each Investor whose Registrable Securities are included in any Registration Statement (i) promptly after the same is prepared
and filed with the SEC, if requested by the Investor, one (1) copy of any Registration Statement and any amendment thereto, each
preliminary Prospectus and Prospectus and each amendment or supplement thereto, and each letter written by or on behalf of the Company
to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such
Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment),
and (ii) such number of copies of a Prospectus, including a preliminary Prospectus, and all amendments and supplements thereto and
such other documents as each Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned
by such Investor that are covered by such Registration Statement;
(e) use
commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if
such order is issued, obtain the withdrawal of any such order at the earliest practical moment;
(f) prior
to any public offering of Registrable Securities, use commercially reasonable efforts to register or qualify or cooperate with the Investors
and their counsel in connection with the registration or qualification of such Registrable Securities for the offer and sale under the
securities or blue sky laws of such jurisdictions requested by the Investors and do any and all other commercially reasonable acts or
things necessary or advisable to enable the distribution in such jurisdictions of the Registrable Securities covered by the Registration
Statement; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify
to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(f), (ii) subject
itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this Section 3(f), or (iii) file
a general consent to service of process in any such jurisdiction;
(g) use
commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on The Nasdaq Global
Market (or the primary securities exchange, interdealer quotation system or other market on which similar securities issued by the Company
are then listed);
(h) promptly
notify the Investors, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon the happening of any event
as a result of which, the Prospectus includes an untrue statement of a material fact or omits to state any material fact required to
be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing (provided that
such notice shall not, without the prior written consent of an Investor, disclose to such Investor any material nonpublic information
regarding the Company), and promptly prepare, file with the SEC and furnish to such holder a supplement to or an amendment of such Prospectus
as may be necessary so that such Prospectus shall not include an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing;
(i) otherwise
use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934
Act, including, without limitation, Rule 172 under the 1933 Act, file any final Prospectus, including any supplement or amendment
thereof, with the SEC pursuant to Rule 424 under the 1933 Act, promptly inform the Investors in writing if, at any time during the
Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investors
are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may
be reasonably necessary to facilitate the registration of the Registrable Securities hereunder; and make available to its security holders,
as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period
of at least twelve (12) months, beginning after the effective date of each Registration Statement, which earnings statement shall
satisfy the provisions of Section 11(a) of the 1933 Act, including Rule 158 promulgated thereunder (for the purpose of
this subsection 3(i), “Availability Date” means the 45th day following the end of the fourth fiscal quarter that includes
the effective date of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter of the Company’s
fiscal year, “Availability Date” means the 90th day after the end of such fourth fiscal quarter);
(j) if
requested by an Investor, (i) as soon as reasonably practicable, incorporate in a prospectus supplement or post-effective amendment
such information as an Investor reasonably requests to be included therein relating to the sale and distribution of Registrable Securities,
including, without limitation, information with respect to the number of Registrable Securities being offered or sold, the purchase price
being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering; (ii) as soon
as reasonably practicable, make all required filings of such prospectus supplement or post-effective amendment after being notified of
the matters to be incorporated in such prospectus supplement or post-effective amendment; and (iii) as soon as reasonably practicable,
supplement or make amendments to any Registration Statement if reasonably requested by an Investor holding any Registrable Securities;
(k) within
two (2) Business Days after a Registration Statement which covers Registrable Securities is ordered effective by the SEC (if not
automatically effective upon filing), deliver to the transfer agent for such Registrable Securities (with copies to the Investors whose
Registrable Securities are included in such Registration Statement) confirmation that such Registration Statement has been declared effective
by the SEC; and
(l) with
a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or regulation
of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, covenant and
agree to: (i) make and keep adequate current public information available, as those terms are understood and defined in Rule 144,
until the earlier of (A) six months after such date as all of the Registrable Securities may be sold without restriction by the
holders thereof pursuant to Rule 144 or any other rule of similar effect or (B) such date as all of the Registrable Securities
shall have been resold or shall have otherwise ceased to be Registrable Securities; (ii) file with the SEC in a timely manner all
reports and other documents required of the Company under the 1934 Act; and (iii) furnish to each Investor upon request, as long
as such Investor owns any Registrable Securities, (A) a written statement by the Company that it has complied with the reporting
requirements of the 1934 Act, (B) a copy of the Company’s most recent Annual Report on Form 10-K or Quarterly Report
on Form 10-Q, and (C) such other information as may be reasonably requested in order to avail such Investor of any rule or
regulation of the SEC that permits the selling of any such Registrable Securities without registration.
4. Due
Diligence Review; Information. The Company shall, upon reasonable prior notice, make available, during normal business hours and
for reasonable periods, for inspection and review by the Investors, and advisors to and representatives of the Investors (who may or
may not be affiliated with the Investors and who are reasonably acceptable to the Company) (collectively, the “Inspectors”),
all pertinent financial and other records, and all other pertinent corporate documents and properties of the Company (collectively, the
“Records”), as may be reasonably necessary for the purpose of such review, and cause the Company’s officers,
directors and employees, within a reasonable time period, to supply all such information reasonably requested by the Inspectors (including,
without limitation, in response to all questions and other inquiries reasonably made or submitted by any of them), prior to and from
time to time after the filing and effectiveness of such Registration Statement for the sole purpose of enabling the Investors and their
accountants and attorneys to conduct initial and ongoing due diligence with respect to the Company and the accuracy of such Registration
Statement; provided, however, that each Inspector shall have agreed in writing to hold in strict confidence and to not make any disclosure
(except to such Investor) or use of any Record or other information which the Company determines in good faith to be confidential, and
of which determination the Inspectors are so notified, unless (a) the disclosure of such Records is necessary to avoid or correct
a misstatement or omission in any Registration Statement or is otherwise required under the 1933 Act, (b) the release of such Records
is ordered pursuant to a final, non-appealable subpoena or order from a court or government body of competent jurisdiction, or (c) the
information in such Records has been made generally available to the public other than by disclosure in violation of this Section 4
or any other Transaction Document.
Notwithstanding the foregoing, the Company shall
not disclose material nonpublic information to the Investors, or to advisors to or representatives of the Investors, unless prior to
the disclosure of such information the Company identifies such information as being material nonpublic information and provides the Investors,
such advisors and such representatives with the opportunity to accept or refuse to accept such material nonpublic information for review
and any Investor wishing to obtain such information enters into an appropriate confidentiality and non-use agreement with the Company
with respect thereto.
5. Obligations
of the Investors.
(a) Each
Investor shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the intended
method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect the registration of such Registrable
Securities, and shall execute such documents in connection with such registration as the Company may reasonably request. At least five
(5) Business Days prior to the first anticipated filing date of any Registration Statement, the Company shall notify each Investor
of the information the Company requires from such Investor if such Investor elects to have any of the Registrable Securities included
in such Registration Statement. An Investor shall provide such information, including but not limited to a completed questionnaire substantially
in the form of Exhibit B, to the Company at least three (3) Business Days prior to the first anticipated filing date
of such Registration Statement if such Investor elects to have any of the Registrable Securities included in such Registration Statement.
(b) Each
Investor, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company
in connection with the preparation and filing of a Registration Statement hereunder, unless such Investor has notified the Company in
writing of its election to exclude all of its Registrable Securities from such Registration Statement.
(c) Each
Investor agrees that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay pursuant to
Section 2(c)(ii) or (ii) the happening of an event pursuant to Section 3(h) hereof, such Investor will immediately
discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities, until
the Investor is advised by the Company that such dispositions may again be made.
(d) Each
Investor covenants and agrees that it will comply with the prospectus delivery requirements of the 1933 Act as applicable to it or an
exemption therefrom in connection with sales of Registrable Securities pursuant to any Registration Statement.
6. Indemnification.
(a) Indemnification
by the Company. The Company will indemnify and hold harmless each Investor and its officers, directors, members, employees and agents,
and each other person, if any, who controls such Investor within the meaning of the 1933 Act, against any losses, claims, damages or
liabilities, joint or several, to which they may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages
or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement
or omission or alleged omission of any material fact contained in any Registration Statement, any preliminary Prospectus or final Prospectus,
or any amendment or supplement thereof or (ii) any violation by the Company or its agents of any rule or regulation promulgated
under the 1933 Act applicable to the Company or its agents and relating to action or inaction required of the Company in connection with
such registration, and will reimburse such Investor, and each such officer, director, member, employee, agent and each such controlling
person for any legal or other documented, out-of-pocket expenses reasonably incurred by them in connection with investigating or defending
any such loss, claim, damage or liability (or action in respect thereof); provided, however, that the Company will not be liable in any
such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon (i) an untrue statement
or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by such Investor or any
such controlling person in writing specifically for use in such Registration Statement or Prospectus; (ii) the use by an Investor
of an outdated or defective Prospectus after the Company has notified such Investor in writing that such Prospectus is outdated or defective;
(iii) an Investor’s failure to send or give a copy of the Prospectus or supplement (as then amended or supplemented), if required
(and not satisfied by filing thereof pursuant to Rule 172 under the 1933 Act or otherwise exempted) to the Persons asserting an
untrue statement or omission or alleged untrue statement or omission at or prior to the written confirmation of the sale of Registrable
Securities; or (iv) an Investor’s bad faith, gross negligence, recklessness, fraud or willful misconduct.
(b) Indemnification
by the Investors. Each Investor agrees, severally but not jointly, to indemnify and hold harmless, to the fullest extent permitted
by law, the Company, its directors, officers, employees, stockholders and each person who controls the Company (within the meaning of
the 1933 Act) against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any untrue
statement of a material fact or any omission of a material fact required to be stated in any Registration Statement or Prospectus or
preliminary Prospectus or amendment or supplement thereto or necessary to make the statements therein not misleading, to the extent,
but only to the extent that such untrue statement or omission is contained in any information furnished in writing by such Investor to
the Company specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto. Except to the
extent that any such losses, claims, damages, liabilities or expenses are finally judicially determined to have resulted from an Investor’s
bad faith, gross negligence, recklessness, fraud or willful misconduct, in no event shall the liability of an Investor be greater in
amount than the dollar amount of the proceeds (net of all expenses paid by such Investor in connection with any claim relating to this
Section 6 and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission)
received by such Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification
obligation.
(c) Conduct
of Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt written notice to the
indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume
the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification
hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses
of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees
or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory
to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest
exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying
party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party
shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any
indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except
to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim
or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be
liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying
party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed,
effect any settlement of or consent to the entry of any judgment with respect to any pending proceeding in respect of which any indemnified
party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement
(i) includes an unconditional release of such indemnified party from all liability in respect of or arising out of such claims or
proceedings that are the subject matter of such proceeding, (ii) imposes no liability or obligation on the indemnified party and
(iii) does not include any admission of fault, culpability, wrongdoing or malfeasance by or on behalf of the indemnified party.
(d) Contribution.
If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable to an indemnified
party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to
the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate
to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations.
No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the 1933 Act shall be entitled to contribution
from any person not guilty of such fraudulent misrepresentation. Except to the extent that any such losses, claims, damages or liabilities
are finally judicially determined to have resulted from a holder of Registrable Securities’ bad faith, gross negligence, recklessness,
fraud or willful misconduct, in no event shall the contribution obligation of such holder be greater in amount than the dollar amount
of the proceeds (net of all expenses paid by such holder in connection with any claim relating to this Section 6 and the amount
of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.
7. Miscellaneous.
(a) Effective
Date. This Agreement shall be effective as of the Closing, and if the Closing has not occurred on or prior to fifth Trading Day following
the date of the Purchase Agreement, unless otherwise mutually agreed, then this Agreement shall be null and void.
(b) Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Required
Investors. Notwithstanding the foregoing, this Agreement may not be amended and the observance of any term of this Agreement may not
be waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver applies to all Investors
in the same fashion.
(c) Notices.
All notices and other communications provided for or permitted hereunder shall be made as set forth in Section 9.4 of the Purchase
Agreement.
(d) Assignments
and Transfers by Investors. The provisions of this Agreement shall be binding upon and inure to the benefit of the Investors and
their respective successors and assigns. An Investor may transfer or assign, in whole or from time to time in part, to one or more persons
its rights hereunder in connection with the transfer of Registrable Securities by such Investor to such person, provided that such Investor
complies with all laws applicable thereto, and the provisions of the Purchase Agreement, and provides written notice of assignment to
the Company promptly after such assignment is effected, and such person agrees in writing to be bound by all of the provisions contained
herein.
(e) Assignments
and Transfers by the Company. This Agreement may not be assigned by the Company (whether by operation of law or otherwise) without
the prior written consent of the Required Investors, provided, however, that in the event that the Company is a party to a merger, consolidation,
share exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of another
Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction and without prior written
consent of the Required Investors, be deemed to have assumed the obligations of the Company hereunder, the term “Company”
shall be deemed to refer to such Person and the term “Registrable Securities” shall be deemed to include the securities received
by the Investors in connection with such transaction unless such securities are otherwise freely tradable by the Investors after giving
effect to such transaction.
(f) Benefits
of the Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective permitted
successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of
this Agreement, except as expressly provided in this Agreement.
(g) Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
(h) Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement.
(i) Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as
if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by
applicable law, the parties hereby waive any provision of law which renders any provisions hereof prohibited or unenforceable in any
respect.
(j) Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions as may
reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.
(k) Entire
Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive
statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein. This Agreement
supersedes all prior agreements and understandings between the parties with respect to such subject matter.
(l) Governing
Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York. Service of process
in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as
are specified for the giving of notices under this Agreement.
(m) Cumulative
Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.
[remainder of page intentionally left blank]
IN WITNESS WHEREOF, the parties have executed
this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.
COMPANY: |
OCULAR THERAPEUTIX, INC. |
|
|
|
By: |
/s/ Donald Notman |
|
|
Name: Donald Notman |
|
|
Title: Chief Financial Officer |
INVESTOR: |
|
|
By: |
|
|
|
Name: |
|
|
Title: |
Exhibit A
Plan of Distribution
The selling stockholders, which as used herein
includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common
stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer,
may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common
stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions
may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying
prices determined at the time of sale, or at negotiated prices.
The selling stockholders may use any one or more
of the following methods when disposing of shares or interests therein:
– ordinary brokerage transactions and transactions
in which the broker-dealer solicits purchasers;
– block trades in which the broker-dealer
will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
– purchases by a broker-dealer as principal
and resale by the broker-dealer for its account;
– an exchange distribution in accordance
with the rules of the applicable exchange;
– privately negotiated transactions;
– short sales and settlement of short sales;
– through the writing or settlement of options
or other hedging transactions, whether through an options exchange or otherwise;
– broker-dealers may agree with the selling
stockholders to sell a specified number of such shares at a stipulated price per share;
– a combination of any such methods of sale;
and
– any other method permitted by applicable
law.
The selling stockholders may, from time to time,
pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under
this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act of 1933, as amended (the “Securities Act”), amending the list of selling stockholders to include the pledgee,
transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer
the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the
selling beneficial owners for purposes of this prospectus.
In connection with the sale of our common stock
or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders
may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the
common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions
with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to
such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial
institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The aggregate proceeds to the selling stockholders
from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any.
Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole
or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from
this offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price of the warrants.
The selling stockholders also may resell all or
a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet
the criteria and conform to the requirements of that rule.
The selling stockholders and any underwriters,
broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters” within
the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of
the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are deemed “underwriters”
within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.
To the extent required, the shares of our common
stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any
agents, dealers or underwriters, and any applicable commissions or discounts with respect to a particular offer will be set forth in
an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this
prospectus.
In order to comply with the securities laws of
some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers.
In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from
registration or qualification requirements is available and is complied with.
We have advised the selling stockholders that
the anti-manipulation rules of Regulation M under the Securities Exchange Act of 1934, as amended, may apply to sales of shares
in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will
make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the
purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer
that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the
Securities Act.
We have agreed to indemnify the selling stockholders
against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares
offered by this prospectus.
We have agreed with the selling stockholders to
use commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to remain continuously
effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and
in accordance with such registration statement or (2) the date on which all of the shares may be sold without restriction pursuant
to Rule 144 of the Securities Act.
Exhibit B
Form of Selling Stockholder Questionnaire
OCULAR THERAPEUTIX, INC.
SELLING
STOCKHOLDER Questionnaire
Reference is made to that certain registration
rights agreement (the “Registration Rights Agreement”), dated as of February _____, 2024, by and among Ocular
Therapeutix, Inc. (the “Company”) and the parties named therein. Capitalized terms used and not defined herein
shall have the meanings given to such terms in the Registration Rights Agreement.
The undersigned holder of the Registrable Securities
(the “undersigned or “Selling Stockholder”) is providing this Selling Stockholder Questionnaire pursuant to
Section 5(a) of the Registration Rights Agreement. The undersigned, by signing and returning this Selling Stockholder Questionnaire,
understands that it will be bound by the terms and conditions of this Selling Stockholder Questionnaire and the Registration Rights Agreement.
The undersigned hereby acknowledges its indemnity obligations pursuant to Section 6(b) of the Registration Rights Agreement.
The undersigned further acknowledges that the
Company intends to use the information set forth below in preparing a resale registration statement (the “Resale Registration
Statement”) relating to the Registrable Securities. The undersigned understands that failure to provide the requested information
may result in the Company’s exclusion of the undersigned Registrable Securities from the Resale Registration Statement.
The undersigned provides the following information
to the Company and represents and warrants that such information is accurate and complete.
PART A. | BACKGROUND INFORMATION |
(1) | (a) | Full Legal Name of the Selling Stockholder: |
| | |
| | |
|
| | |
| (b) | Full Legal Name of Registered Holder (if not the same as (a) above)
through which Registrable Securities listed in (3) below are held: |
| | |
| | |
|
| | |
|
| (c) | Full Legal Name of DTC Participant (if applicable
and if not the same as (b) above) through which Registrable Securities listed in (3) below are held: |
| | |
|
(2) | Address for Notices to the Selling Stockholder: |
| |
| |
|
| |
|
| |
|
| Telephone: |
|
|
| |
|
|
| Contact Person: |
|
|
| (3) | Beneficial Ownership of Registrable Securities
(the securities being purchased pursuant to the Purchase
Agreement): |
| (a) | Type and Principal Amount/Number of Registrable
Securities beneficially owned: |
| | |
| | |
|
| | |
| (b) | CUSIP No(s). of such Registrable Securities
beneficially owned: |
| | |
| | |
|
| (4) | Beneficial Ownership
of Other Securities of the Company Owned by the Selling Stockholder: |
Except as set forth below in this Item (4), the
Selling Stockholder is not the beneficial or registered owner of any securities of the Company other than the Registrable Securities
listed above in Item (3).
| (a) | Type and Amount of Other Securities beneficially
owned by the Selling Stockholder: |
| | |
| | |
|
| (b) | CUSIP No(s). of such Other Securities beneficially
owned: |
| | |
| | |
|
PART B. | RESALE REGISTRATION STATEMENT
QUESTIONS |
| 1. | Affiliation
with Broker-Dealers: Is the undersigned a registered broker-dealer or an affiliate of a registered
broker-dealer? For purposes of this question, an “affiliate” of a specified person
or entity means a person or entity that directly, or indirectly through one or more intermediaries,
controls or is controlled by, or is under common control with, the person or entity specified. |
| | |
| | Yes ¨ No
¨ |
| | |
| | If so, please answer the remaining questions in this section. |
| | |
| | Please identify the registered broker-dealer(s) and describe the nature
of the affiliation(s) between the undersigned and any registered broker-dealers: |
| | |
| 2. | If the
Registrable Securities are being purchased by you other than in the ordinary course of business,
please describe the circumstances: |
| | |
| | |
| | |
| | |
| 3. | If you,
at the time of purchasing the Registrable Securities, will have any agreements or understandings,
directly or indirectly, with any person to distribute the Registrable Securities, please
describe such agreements or understandings: |
| | |
| | |
| | |
| | |
| 4. | Relationship
with the Company: |
| (A) | Have you or any of your affiliates, officers,
directors or principal equity holders (owners of 5% or more of the equity securities of the
undersigned) held any position or office or have you had any other material relationship
with the Company (or its predecessors or affiliates) within the past three years? |
| | |
| Yes ¨ No
¨ |
| | |
| (B) | If so, please state the nature and duration of your relationship with the
Company: |
| | |
| | |
| | |
| | |
| 5. | Plan
of Distribution: Except as set forth below, the undersigned intends to distribute its Registrable
Securities pursuant to the Resale Registration Statement in accordance with the “Plan
of Distribution” that will be included therein, a copy of which is attached as Exhibit A
to the Registration Rights Agreement by and among the Company and the Investors: |
| | |
| | State any exceptions here: |
| | |
|
| | |
|
| | |
|
| | |
|
| 6. | Potential
Nature of Beneficial Holding: The purpose of this question is to identify the ultimate natural
person(s) or publicly held entity that will exercise(s) sole or shared voting or
dispositive power over the Registrable Securities. |
| (A) | Is the undersigned required to file, or
is it a wholly-owned subsidiary of a company that is required to file, periodic and other
reports (for example, Forms 10-K, 10-Q, 8-K) with the Securities and Exchange Commission
(the “SEC”) pursuant to section 13(a) or 15(d) of the Exchange
Act? |
| | |
| | Yes ¨ No
¨ |
| (B) | State whether the undersigned is a subsidiary
of an investment company, registered under the Investment Company Act of 1940: |
| | |
| | Yes ¨ No
¨ |
| | |
| If a subsidiary, please identify the publicly-held parent entity: |
| |
| |
|
| |
|
| |
|
| |
| |
If you answered “Yes” to these two questions (Part B, clauses 6(A) and (B)), you may skip the
next question, and proceed to the signature page of this Questionnaire. |
| (C) | Please identify the controlling person(s) of
the undersigned (the “Controlling Entity”). If the Controlling Entity
is not a natural person or a publicly held entity, please identify each controlling person(s) of
such Controlling Entity. This process should be repeated until you reach natural persons
or a publicly held entity that will exercise sole or shared voting or dispositive power over
the Registrable Securities: |
| | |
| | |
| | |
| | |
| | |
| | Please find below an example of the requested natural person disclosure: |
| | |
| | The securities will be held by [VC Fund I] and [VC Fund II]. The [sole
general partner] of [VC Fund I] and [VC Fund II] is [VC Management LLC]. The [managers] of [VC Management
LLC] are [John Smith] and [Jane Doe]. These individuals may be deemed to have shared voting and investment
power of the securities held by [VC Fund I] and [VC Fund II]. Each of these individuals will disclaim beneficial
ownership of such securities, except to the extent of his or her pecuniary interest therein. |
| (D) | Please provide contact information for
all controlling persons and Controlling Entities identified in Part B, clause 6(C) above: |
Name of controlling person
or Controlling Entity (including contact person for Controlling Entities) |
Mailing
Address |
E-Mail
Address |
Telephone
Number |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company hereby advises the Investor that
the SEC currently takes the position that coverage of Short Sales (as defined in the Purchase Agreement) of shares of common stock “against
the box” prior to effectiveness of a resale registration statement with securities included in such registration statement would
be a violation of Section 5 of the Securities Act, as set forth in Item 239.10 of the Securities Act Rules Compliance and Disclosure
Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance.
If you need more space for any response, please
attach additional sheets of paper. Please be sure to indicate your name and the number of the item being responded to on each such additional
sheet of paper, and to sign each such additional sheet of paper before attaching it to this Questionnaire. Please note that you may be
asked to answer additional questions depending on your responses to the above questions.
Certain legal consequences arise from being named
as a selling stockholder in the Resale Registration Statement and the related prospectus. Accordingly, holders and beneficial owners
of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being
named as a selling stockholder in the Resale Registration Statement and the related prospectus.
By signing below, the undersigned elects to include
the Registrable Securities owned by it in the Registration Statement and consents to the disclosure of the information contained herein
and the inclusion of such information in the Resale Registration Statement, any amendments thereto and the related prospectus or other
filings with the SEC. The undersigned understands that such information will be relied upon by the Company in connection with the preparation
or amendment of the Resale Registration Statement and the related prospectus.
The Selling Stockholder acknowledges that it
understands its obligations to comply with the provisions of the Securities Exchange Act of 1934, as amended, and the rules thereunder
relating to stock manipulation, particularly Regulation M thereunder (or any successor rules or regulations), in connection with
any offering of Registrable Securities pursuant to the Resale Registration Agreement. The Selling Stockholder agrees that neither it
nor any person acting on its behalf will engage in any transaction in violation of such provisions.
The undersigned agrees to notify the Company
immediately of any changes in the foregoing information and to furnish any supplementary information that may be appropriate.
[Signature Page Follows]
IN WITNESS WHEREOF, the undersigned has executed
this Questionnaire this ____ day of ___________, 2024, and declares that it is truthful and correct.
A. FOR
EXECUTION BY AN ENTITY:
|
| Entity Name: |
|
| |
| |
|
|
| |
By: | |
|
Date | |
| |
|
| |
Print Name: | |
|
| |
Title: | |
| B. | ADDITIONAL SIGNATURES (if required
by partnership, corporation or trust document): |
|
| Entity Name: |
|
| |
| |
|
|
| |
By: | |
|
Date | |
| |
|
| |
Print Name: | |
|
| |
Title: | |
|
| Entity Name: |
|
| |
| |
|
|
| |
By: | |
|
Date | |
| |
|
| |
Print Name: | |
|
| |
Title: | |
| C. | FOR EXECUTION BY
AN INDIVIDUAL: |
Exhibit 10.3
EMPLOYMENT AGREEMENT
This EMPLOYMENT AGREEMENT
(the “Agreement”) sets forth the terms and conditions of your employment with Ocular Therapeutix, Inc., and will be effective
as of February 21, 2024 (the “Effective Date”). In consideration of the mutual covenants contained in this Agreement,
the Company and Executive agree as follows:
1. Employment.
The Company agrees to employ Executive and Executive agrees to be employed by the Company on the terms and conditions set forth in this
Agreement.
(a) Capacity.
Executive shall serve the Company as Executive Chairman of the Board of Directors (the “Board”), shall report to the Board
and shall have such duties and responsibilities as are customary for such position (which shall include leading the Board, leading the
Company’s strategic reviews and guiding the Company’s C-Suite executives). The Chief Executive Officer of the Company
shall report to the Board and to Executive in his capacity as Executive Chairman of the Board.
(b) Devotion
of Duties; Representations. During the Term of Executive’s employment with the Company, Executive shall devote Executive’s
reasonable best efforts and substantially all of Executive’s business time and energies to the business and affairs of the Company.
During the Term of Executive’s employment with the Company, Executive shall not, without the prior written approval of the Company
(by action of the Board), which approval shall not be unreasonably withheld and, for the avoidance of doubt, Executive’s board of
directors position set forth on Exhibit A has been approved), undertake any other employment from any person or entity or
serve as a director of any other company; provided, however, that (i) the Company will entertain requests as to such other employment
or directorships in good faith, (ii) Executive shall be permitted to manage his personal investments, (iii) Executive shall
be permitted to serve on non-for-profit boards and engage in civil and educational activities, provided, that, such service or engagement
does not violate this Agreement or any other agreement between Executive and the Company, interfere with the performance of Executive's
duties for the Company, or present a conflict of interest with the Company's business interest, and (iv) Executive will be eligible
to participate in any policy relating to outside activities that is applicable to the senior executives of the Company and approved by
the Board after the date hereof. Executive’s normal place of work will be remote in Arizona. However, Executive agrees to travel
on any business of the Company as may be required for the performance of Executive’s duties. Executive agrees to abide by the rules,
regulations, instructions, personnel practices and policies of the Company and any changes therein that may be adopted from time to time
by the Company.
2. Term
of Employment.
(a) Executive’s
employment hereunder shall commence as of the Effective Date. Executive shall be employed at-will, meaning that subject to the provisions
herein, either the Company or Executive may terminate Executive’s employment at any time for any legal reason.
(b) Notwithstanding,
Executive’s employment hereunder shall automatically be terminated upon the first to occur of the following:
(i) Immediately
upon Executive’s death;
(ii) By
the Company, by written notice to Executive effective as of the date of such notice (or on such other date as specified in such notice):
(A) Following
the Disability of Executive. “Disability” means that Executive is unable to perform his duties hereunder by reason of any
mental, physical or other disability for a period of at least three (3) months, as determined by a qualified physician that is mutually
selected by the Company and Executive. Notwithstanding the foregoing, for any payments or benefits hereunder or pursuant to any other
agreement between the Company and Executive, in either case that are subject to Section 409A of the Internal Revenue Code of 1986,
as amended (the “Code”) and the guidance issued thereunder, such Disability must result in Executive becoming “Disabled”
within the meaning of Section 409A(a)(2)(C). (In this Agreement we refer to Section 409A of the Code and any guidance issued
thereunder as “Section 409A.”); or
(B) For
Cause (as defined below); or
(C) Without
Cause;
(iii) By
Executive:
(A) At
any time by written notice to the Company, effective thirty (30) days after the date of such notice, which notice period the Company may
waive in whole or in part at its sole discretion; or
(B) By
written notice to the Company with Good Reason (as defined below), effective on the date specified in such notice.
The period of Executive’s employment by
the Company under this Agreement is referred to herein as the “Term.”
(c) Definition
of “Cause”. For purposes of this Agreement, “Cause” shall mean: (i) the willful and continued refusal
by Executive to follow a lawful and material directive of the Board (other than such a refusal as a result of physical or mental disability);
(ii) any action or omission by Executive involving willful misconduct or gross negligence with regard to the Company, which has a
detrimental effect on the Company; (iii) Executive’s conviction of a felony, either in connection with the performance of Executive’s
obligations to the Company or which otherwise shall adversely affect Executive’s ability to perform such obligations or shall materially
adversely affect the business activities, reputation, goodwill or image of the Company; (iv) the material breach of a fiduciary duty
to the Company; or (v) the material breach by Executive of any of the provisions of this Agreement, provided that any breach of Executive’s
obligations with respect to Sections 5 or 6 of this Agreement, subject to the cure provision in the next sentence, shall be deemed “material.”
In respect of the events described in clauses (i) and (v) above, the Company shall give Executive notice of the failure of performance
or breach, reasonable as to time, place and manner in the circumstances, and a 30-day opportunity to cure, provided that such failure
of performance or breach is reasonably amenable to cure as determined by the Company in its sole good faith discretion. Poor performance
shall not in and of itself be Cause. Executive shall not be terminated for Cause as a result of actions or inactions in accordance with
instructions from the Board or counsel to the Company. Executive may only be terminated for Cause following a good faith determination
by a majority of the Board (excluding Executive) as documented in writing and after Executive is provided with the reasonable ability
to appear before the Board.
(d) Definition
of “Good Reason”. For purposes of this Agreement, a “Good Reason” shall mean any of the following, unless
(i) the basis for such Good Reason is cured within a reasonable period of time (determined in the light of the cure appropriate to
the basis of such Good Reason, but in no event less than thirty (30) nor more than ninety (90) days) after the Company receives written
notice (which must be received from Executive within ninety (90) days following the initial existence of the condition giving rise to
such Good Reason) specifying the basis for such Good Reason or (ii) Executive has expressly consented in writing to the condition
that would otherwise be a basis for Good Reason. Further, Executive needs to resign within 30 days after the Company has failed to cure
the Good Reason(s):
(i) A
change required by the Company in the principal location at which Executive provides services to the Company to a location more than thirty
(30) miles from such principal location (which change, the Company has reasonably determined as of the date hereof, would constitute a
material change in the geographic location at which Executive provides services to the Company), provided that such a relocation shall
not be deemed to occur under circumstances where Executive’s responsibilities require him to work at a location other than Executive’s
principal location for a reasonable period of time;
(ii) A
material adverse change by the Company in Executive’s title, duties, authority or responsibilities as Executive Chairman of the
Company which causes Executive’s position with the Company to become of materially less responsibility or authority, including (A) following
a Corporate Change, Executive’s no longer being Executive Chairman of a publicly traded entity where such change is not remedied
within ten (10) business days after written notice thereof by Executive or (B) any failure of the Board to reappoint Executive
as Executive Chairman or renominate Executive for election as a member of the Board;
(iii) A
reduction in Executive’s Base Salary or Target Bonus Percentage;
(iv) A
material breach of this Agreement, any material equity award agreement or other written compensation agreement by the Company which has
not been cured within thirty (30) days after written notice thereof by Executive; or
(v) Failure
to obtain the assumption (assignment) of this Agreement by any successor to the Company.
(e) Definition
of “Corporate Change”. For purposes of this Agreement, “Corporate Change” shall mean the occurrence of any
of the following events:
(i) the
acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership of any capital stock of the
Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 under the Exchange Act) 50% or
more of either (x) the then-outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”)
or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of
directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this Section 2(e) the
following acquisitions shall not constitute a Corporate Change: (A) any acquisition directly from the Company or (B) any acquisition
by any entity pursuant to a Business Combination (as defined below) which complies with clauses (x), (y) and (z) of Section 2(e)(iii) of
this definition;
(ii) a
change in the composition of the Board that results in the Continuing Directors (as defined below) no longer constituting a majority of
the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term “Continuing Director”
means at any date a member of the Board (x) who was a member of the Board on the date of hereof or (y) who was nominated or
elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or
election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors
at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose
initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal
of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or
(iii) the
consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company or a sale or other disposition
of all or substantially all of the assets of the Company (a “Business Combination”), unless, immediately following such Business
Combination, each of the following three conditions is satisfied: (x) the Outstanding Company Common Stock and Outstanding Company
Voting Securities immediately prior to such Business Combination represent more than 50% of the then-outstanding shares of common stock
or other common equity and the combined voting power of the then-outstanding securities entitled to vote generally in the election of
directors or other governing body, respectively, of the resulting or acquiring entity in such Business Combination (which shall include,
without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company’s assets
either directly or through one or more subsidiaries) (such resulting or acquiring entity is referred to herein as the “Acquiring
Entity”), (y) no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by the Company or by
the Acquiring Entity) beneficially owns, directly or indirectly, 50% or more of the then-outstanding shares of common stock of the Acquiring
Entity, or of the combined voting power of the then-outstanding securities of such entity entitled to vote generally in the election of
directors or other governing body (except to the extent that such ownership existed prior to the Business Combination) and (z) immediately
following a Business Combination, a majority of the Board of the Acquiring Entity consists of persons who were directors of the Company
immediately prior to the Business Combination.
For purposes of the payment of any payments or
benefits hereunder (including pursuant to Section 4(b) hereof) or pursuant to any other agreement between the Company and Executive,
in either case that are subject to Section 409A, the Corporate Change must constitute a “change in control event” within
the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i).
(f) Resignation
from Other Positions. If, as of the date that Executive’s employment terminates for any reason, Executive is a member of the
Board (or the board of directors of any entity affiliated with the Company), or holds any other offices or positions with the Company
(or any entity affiliated with the Company), Executive shall immediately relinquish and/or resign from any such board memberships, offices
and positions as of the date Executive’s employment terminates. Executive agrees to execute such documents and take such other actions
as the Company may request to reflect such relinquishments and/or resignation(s).
3. Compensation.
(a) Base
Salary. Executive’s base salary during the Term shall be at the rate of $540,000 per year (the “Base Salary”), subject
to annual review for increase but not decrease. Executive’s Base Salary shall be payable in substantially equal installments in
accordance with the Company’s payroll practices as in effect from time to time, less any amounts required to be withheld under applicable
law. Any increased amount of Base Salary shall be treated as the Base Salary for purposes of this Agreement.
(b) Bonus.
In addition to the Base Salary, the Company shall pay Executive an annual bonus (the “Bonus”) as determined by the Board based
on the level of achievement of the corporate goals for all Company senior executive officers, which determination shall be made solely
in the good faith reasonable discretion of the Board (it being understood that Executive’s target annual bonus shall be 65% of Base
Salary, subject to review for increase but not decrease (the “Target Bonus Percentage”)), and subject to higher or lower payment
based upon performance. Except as provided herein, Executive must be an active employee of the Company as of December 31 of the relevant
calendar year in order to be eligible for and to earn any Bonus for that year. Any Bonus for a particular year shall be paid or provided
to Executive in a lump sum no later than March 15th of the calendar year following the calendar year in which the Bonus was approved
by the Board and earned.
(c) Equity
Grants.
(i)
Stock Option Grant. As a material inducement to
Executive entering into employment with the Company, the Company shall grant to Executive on February 22, 2024 (the
“Grant Date”) an option to purchase 1,282,469 shares of the Company’s common stock (the “Initial
Option”). The Initial Option (A) is subject to adjustment for stock splits, combinations or other recapitalizations,
(B) will have an exercise price per share equal to the last reported sale price per share of the common stock on the Nasdaq
stock exchange on the Grant Date of the Initial Option, (C) will be granted under the Company’s 2019 Inducement Stock
Incentive Plan, as amended (the “2019 Inducement Plan”), as an “inducement grant” within the meaning of
Nasdaq Listing Rule 5635(c)(4), (D) will be a non-qualified stock option for United States tax purposes, (E) will
vest in equal monthly installments beginning on the Effective Date and ending on the fourth anniversary of the Effective Date and
(F) will be subject to all of the terms and conditions set forth in the 2019 Inducement Plan and a written agreement covering
the Initial Option, provided that the Initial Option agreement shall provide that the exercise price of the option may be satisfied
through a “net exercise” as described in Section 5(e)(4) of the 2019 Inducement Plan (such option agreement
attached hereto as Exhibit B).
(ii) Restricted
Stock Unit Grant. As a material inducement to Executive entering into employment with the Company, the Company shall grant to Executive
on the Grant Date a restricted stock unit award with respect to 854,979 shares of the Company’s common stock (the “Initial
RSU”). The Initial RSU (A) is subject to adjustment for stock splits, combinations or other recapitalizations, (B) shall
be granted under the 2019 Inducement Plan as an “inducement grant” within the meaning of Nasdaq Listing Rule 5635(c)(4),
(C) will vest in equal quarterly installments beginning on the Effective Date and ending on the third anniversary of the Effective
Date and (D) will be subject to all of the terms and conditions set forth in the 2019 Inducement Plan and a written agreement covering
the Initial RSU (such RSU agreement attached hereto as Exhibit C).
(iii) Annual
Equity Awards. Executive is eligible for annual equity awards, subject to the approval of the Board and on such terms and conditions
as the Board shall determine, provided that such annual equity awards shall in all events be granted with respect to at least the same
number of shares of Company common stock (and same proportion of types of equity awards) and with at least as favorable vesting and exercisability
as the annual equity awards granted by the Company to the Chief Executive Officer.
(d) Fringe
Benefits. Executive shall be entitled to participate in any employee benefit plans that the Company makes available to its executives
(including, without limitation, group life, disability, medical, dental and other insurance, retirement, pension, profit-sharing and similar
plans) (collectively, the “Fringe Benefits”). These Fringe Benefits may be discontinued, modified or changed from time to
time at the sole discretion of the Company, provided, that, Executive shall be treated no less favorably than other Company senior executive
officers. Where a particular Fringe Benefit is subject to a formal plan (for example, medical or life insurance), eligibility to participate
in and receive any particular Fringe Benefit is governed solely by the applicable plan document, and eligibility to participate in such
plan(s) may be dependent upon, among other things, a physical examination, subject to applicable law. Executive shall be eligible
to take up to 20 days of paid vacation during each year of the Term, subject to the accrual described in the following sentence, to be
taken at such time or times as shall be mutually convenient and consistent with Executive’s duties and obligations to the Company.
The number of vacation days for which Executive is eligible shall accrue at the rate of 1.67 days per month. Vacation is at all times
subject to the Company’s Time-Off Policy, which the Company may change periodically in its sole discretion.
(e) Reimbursement
of Expenses. During the Term, Executive shall be entitled to reimbursement for all ordinary and reasonable out-of-pocket business
expenses that are reasonably incurred by Executive in furtherance of the Company’s business in accordance with its policies for
senior executives, subject to Section 4(d)(v). Executive shall be permitted to travel business class and shall be reimbursed, if
applicable, by the Company on a tax-neutral basis to Executive.
(f) Legal
Fees. The Company shall pay directly or reimburse Executive for legal fees reasonably incurred by Executive in the negotiation of
this Agreement, not to exceed $55,000, within 30 days following receipt of an invoice therefor, which reimbursement shall be reduced by
applicable tax and other withholdings.
(g) Indemnification.
Executive shall be covered by all applicable indemnification and expense advancement policies of the Company applicable to members of
the Board and senior executive officers generally and shall also be covered by any directors’ and officers’ liability insurance
policy applicable to members of the Board or senior executive officers of the Company.
4. Severance
Compensation
(a) In
the event of any termination of Executive’s employment for any reason, the Company shall pay Executive (or Executive’s estate
or beneficiaries, if applicable) (i) such portion of Executive’s Base Salary as has accrued prior to such termination and have
not yet been paid, (ii) any amounts for expense reimbursement which have been properly incurred or the Company has become obligated
to pay prior to termination and have not been paid as of the date of such termination, (iii) the amount of any Bonus previously granted
to Executive by the Board but not yet paid for the prior fiscal year, which amount shall not include any pro rata portion of any Bonus
which would have been earned if such termination had not occurred, (iv) any amounts for accrued but unused vacation days (as provided
above) and (v) any vested or accrued benefits under the Company’s employee benefits plans (the “Accrued Obligations”).
Such Accrued Obligations shall be paid as follows: (A) for (i) and (iv), the earlier of the next payroll date of the Company
following the date of termination and such date as is required by law, (B) for (iii), when Bonuses are paid to other senior executive
officers of the Company, (C) for (ii), under the Company’s expense reimbursement policy and (D) for (v), under the terms
of the applicable employee benefit plans of the Company.
(b) In
the event that Executive’s employment hereunder is terminated (i) by Executive with Good Reason, (ii) by the Company without
Cause or (iii) on account of Executive’s death or Disability, the Company shall pay to Executive the Accrued Obligations. In
addition, the Executive shall be eligible for the severance benefits set forth in Sections 4(b)(i)-4(b)(iii) below as further described
therein. The receipt of any severance benefits provided in this Section shall be dependent upon Executive’s execution and non-revocation
of a separation and general release of claims agreement in a form attached hereto as Exhibit D (the “Release”).
The Release must be signed and any applicable revocation period with respect thereto must have expired by the sixtieth (60th) day following
Executive’s termination of employment, or such earlier date as determined by the Company. The severance payments and benefits shall
be paid or commence, as applicable, on the first payroll period following the date of the Executive’s termination and an effective
Release (the “Payment Date”). Notwithstanding the foregoing, if the 60th day following Executive’s termination occurs
in the calendar year following the calendar year in which Executive’s employment terminates, the Payment Date shall be no earlier
than January 1 of such subsequent calendar year, but in any event on the first payroll date following the date of Executive’s
termination and an effective Release in such subsequent calendar year.
(i)
Base Salary; Bonus. In the event that Executive’s employment is
terminated by Executive with Good Reason or by the Company without Cause, and in either case such termination occurs outside of a
Protected Period (as defined below), the Company shall continue to pay Executive his then Base Salary (not taking into account any
reduction to Base Salary which would constitute Good Reason), less applicable taxes and withholdings, for twelve (12) months
following Executive’s termination in accordance with the Company’s payroll practice, beginning on the Payment Date;
provided, that the first installment will include all amounts that otherwise would have been paid to Executive from the date
Executive’s employment terminates through the Payment Date had the Release become effective on the date of termination. In the
event that Executive’s employment is terminated by Executive with Good Reason or by the Company without Cause, and in either
case such termination occurs during the period commencing on the date ninety (90) days prior to the closing of a Corporate Change
and ending twelve (12) months following a Corporate Change (the “Protected Period”), the Company shall pay Executive an
aggregate amount equal to (A) eighteen (18) months of Executive’s then Base Salary (not taking into account any reduction
to Base Salary which would constitute Good Reason) and (B) one and one-half times his Target Annual Bonus (not taking into
account any reduction to the Target Annual Bonus which would constitute Good Reason) for the year in which the termination of
employment occurs, less applicable taxes and withholdings, in a lump sum on the Payment Date. In the event of a termination during
the Protected Period that occurs prior to the occurrence of a Corporate Change such that the Payment Date occurs prior to the
occurrence of the Corporate Change, (x) following the occurrence of the Corporate Change, the Company shall pay Executive the
Protected Period Severance Amount following the Corporate Change, less any severance payments made previously under this
Section 4(b)(i) and (y) if necessary to comply with the provisions of Code Section 409A (as defined below)
certain severance payments shall continue to be made in installments.
(ii) Equity
Awards. In the event that Executive’s employment is terminated by Executive with Good Reason, by the Company without Cause,
or on account of Executive’s death or Disability, the following shall apply:
(A) Any
equity grants that vest solely based on Executive’s continued performance of services shall become vested, exercisable and nonforfeitable
as of the Payment Date with respect to the portion of such award that would have vested, become exercisable or become nonforfeitable
within the 12 month period following the date of termination, provided that with respect to the Initial Option and the Initial RSU, the
portion of such awards that would have vested, become exercisable or become nonforfeitable within the 24 month period following the date
of termination shall become vested, exercisable and nonforfeitable as of the Payment Date. Notwithstanding the foregoing, if the termination
occurs during the Protected Period, one hundred percent (100%) of Executive’s then outstanding unvested equity awards that vest
solely based on Executive’s continued performance of services shall vest, become exercisable and nonforfeitable, as of the Payment
Date.
(B) The
Initial Option shall be exercisable for a period of 24 months following the date of termination.
(C) For
the avoidance of doubt, any equity awards that vest based on the achievement of performance metrics shall be governed by the terms of
the applicable award agreement and shall not be entitled to accelerated vesting pursuant to this Agreement.
(iii) COBRA.
In the event that Executive’s employment is terminated by Executive with Good Reason or by the Company without Cause, should Executive
timely elect and be eligible to continue receiving group medical coverage pursuant to the law known as COBRA, and so long as the Company
can provide such benefit without violating the nondiscrimination requirements of applicable law, the Company will continue to pay the
share of the premium for such coverage that is paid by the Company for active and similarly-situated employees who receive the same type
of coverage, as well as any administrative fee, for twelve (12) months if the termination occurs outside of the Protected Period or eighteen
(18) months if the termination occurs during the Protected Period, subject to applicable law and the terms of the respective policies;
provided that the Company’s obligation to provide the premium payments contemplated herein shall terminate upon Executive’s
becoming eligible for coverage under the medical benefits program of a subsequent employer. The foregoing shall not be construed to extend
any period of continuation coverage (e.g., COBRA) required by Federal law.
(c) The
Company shall have no obligation to pay Executive (or Executive’s estate) any other compensation or provide any other benefit(s) following
such termination except as provided in this Section 4. In no event shall Executive be obligated to seek or obtain other employment
after the date of termination, or take any other action by way of mitigation of the amounts payable to Executive under any of the provisions
of this Agreement, and such amounts shall not be reduced, whether or not Executive obtains other employment, except as provided in Section 4(b)(iii).
(d) Compliance
with Section 409A. Subject to the provisions in this Section 4(d), any severance payments or benefits under this Agreement
shall begin only upon the date of Executive’s “separation from service” (determined as set forth below) which occurs
on or after the date of termination of Executive’s employment. The following rules shall apply with respect to the distribution
of the severance payments and benefits, if any, to be provided to Executive under this Agreement:
(i) It
is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate
“payment” for purposes of Section 409A. Neither the Company nor Executive shall have the right to accelerate or defer
the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.
(ii) If,
as of the date of Executive’s “separation from service” from the Company, Executive is not a “specified employee”
(within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and
terms set forth in this Agreement.
(iii) If,
as of the date of Executive’s “separation from service” from the Company, Executive is a “specified employee”
(within the meaning of Section 409A), then:
(A) Each
installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein,
will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined
under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to
the maximum extent permissible under Section 409A and such payments and benefits shall be paid or provided on the dates and terms
set forth in this Agreement; and
(B) Each
installment of the severance payments and benefits due under this Agreement that is not described in Section 4(d)(iii)(A) above
and that would, absent this subsection (B), be paid within the six-month period following Executive’s “separation from service”
from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, Executive’s
death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum
on the date that is six months and one day following Executive’s separation from service and any subsequent installments, if any,
being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence
shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to
be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation
1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the
exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of Executive’s
second taxable year following the taxable year in which the separation from service occurs.
(iv) The
determination of whether and when Executive’s separation from service from the Company has occurred shall be made in a manner consistent
with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this Section 4(d)(iv),
“Company” shall include all persons with whom the Company would be considered a single employer under Sections 414(b) and
414(c) of the Code.
(v) All
reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A
to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements
that (i) any reimbursement is for expenses incurred during Executive’s lifetime (or during a shorter period of time specified
in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible
for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last
day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject
to set off or liquidation or exchange for any other benefit.
(vi) The
parties intend that the payments and benefits under this Agreement shall be exempt from or shall comply with Section 409A and this
Agreement shall be interpreted consistent with such intent. Notwithstanding anything herein to the contrary, the Company shall have no
liability to Executive or to any other person if the payments and benefits provided hereunder that are intended to be exempt from or compliant
with Section 409A are not so exempt or compliant.
(e) Modified
Section 280G Cutback.
(i) Notwithstanding
any other provision of this Agreement, except as set forth in Section 4(e)(ii), in the event that the Company undergoes a “Change
in Ownership or Control” (as defined below), the Company shall not be obligated to provide to Executive a portion of any “Contingent
Compensation Payments” (as defined below) that Executive would otherwise be entitled to receive to the extent necessary to eliminate
any “excess parachute payments” (as defined in Section 280G(b)(1) of the Code) for Executive. For purposes of this
Section 4(e), the Contingent Compensation Payments so eliminated shall be referred to as the “Eliminated Payments” and
the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision) of the
Contingent Compensation Payments so eliminated shall be referred to as the “Eliminated Amount.”
(ii) Notwithstanding
the provisions of Section 4(e)(i), no such reduction in Contingent Compensation Payments shall be made if (1) the Eliminated
Amount (computed without regard to this sentence) exceeds (2) 100% of the aggregate present value (determined in accordance with
Treasury Regulation Section 1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional taxes that would
be incurred by Executive if the Eliminated Payments (determined without regard to this sentence) were paid to Executive (including federal
and state income taxes on the Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all
of the Contingent Compensation Payments in excess of Executive’s “base amount” (as defined in Section 280G(b)(3) of
the Code), and any withholding taxes). The override of such reduction in Contingent Compensation Payments pursuant to this Section 4(e)(ii) shall
be referred to as a “Section 4(e)(ii) Override.” For purpose of this paragraph, if any federal or state income taxes
would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of
the Eliminated Payment by the maximum combined federal and state income tax rate provided by law.
(iii) For
purposes of this Section 4(e) the following terms shall have the following respective meanings:
(A) “Change
in Ownership or Control” shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial
portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code.
(B) “Contingent
Compensation Payment” shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this
Agreement or otherwise) to a “disqualified individual” (as defined in Section 280G(c) of the Code) and that is contingent
(within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.
(iv) Any
payments or other benefits otherwise due to Executive following a Change in Ownership or Control that could reasonably be characterized
(as determined by the Company) as Contingent Compensation Payments (the “Potential Payments”) shall not be made until the
dates provided for in this Section 4(e)(iv). Within 30 days after each date on which Executive first becomes entitled to receive
(whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine
and notify Executive (with reasonable detail regarding the basis for its determinations) (1) which Potential Payments constitute
Contingent Compensation Payments, (2) the Eliminated Amount and (3) whether the Section 4(e)(ii) Override is applicable.
Within 30 days after delivery of such notice to Executive, Executive shall deliver a response to the Company (the “Executive Response”)
stating either (A) that Executive agrees with the Company’s determination pursuant to the preceding sentence or (B) that
Executive disagrees with such determination, in which case Executive shall set forth (x) which Potential Payments should be characterized
as Contingent Compensation Payments, (y) the Eliminated Amount, and (z) whether the Section 4(e)(ii) Override is applicable.
In the event that Executive fails to deliver an Executive Response on or before the required date, the Company’s initial determination
shall be final. If Executive states in the Executive Response that Executive agrees with the Company’s determination, the Company
shall make the Potential Payments to Executive within three business days following delivery to the Company of the Executive Response
(except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date
on which they are due). If Executive states in the Executive Response that Executive disagrees with the Company’s determination,
then, for a period of 60 days following delivery of the Executive Response, Executive and the Company shall use good faith efforts to
resolve such dispute. If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration
in the greater Boston, Massachusetts area, in accordance with the rules of the American Arbitration Association then in effect. Judgment
may be entered on the arbitrator’s award in any court having jurisdiction. The Company shall, within three business days following
delivery to the Company of the Executive Response, make to Executive those Potential Payments as to which there is no dispute between
the Company and Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until
after such date, which Potential Payments shall be made on the date on which they are due). The balance of the Potential Payments shall
be made within three business days following the resolution of such dispute.
(v) The
Contingent Compensation Payments to be treated as Eliminated Payments shall be determined by the Company by determining the “Contingent
Compensation Payment Ratio” (as defined below) for each Contingent Compensation Payment and then reducing the Contingent Compensation
Payments in order beginning with the Contingent Compensation Payment with the highest Contingent Compensation Payment Ratio. For Contingent
Compensation Payments with the same Contingent Compensation Payment Ratio, such Contingent Compensation Payment shall be reduced based
on the time of payment of such Contingent Compensation Payments with amounts having later payment dates being reduced first. For Contingent
Compensation Payments with the same Contingent Compensation Payment Ratio and the same time of payment, such Contingent Compensation
Payments shall be reduced on a pro rata basis (but not below zero) prior to reducing Contingent Compensation Payments with a lower Contingent
Compensation Payment Ratio. The term “Contingent Compensation Payment Ratio” shall mean a fraction the numerator of which
is the value of the applicable Contingent Compensation Payment that must be taken into account by Executive for purposes of Section 4999(a) of
the Code, and the denominator of which is the actual amount to be received by Executive in respect of the applicable Contingent Compensation
Payment. For example, in the case of an equity grant that is treated as contingent on the Change in Ownership or Control because the
time at which the payment is made or the payment vests is accelerated, the denominator shall be determined by reference to the fair market
value of the equity at the acceleration date, and not in accordance with the methodology for determining the value of accelerated payments
set forth in Treasury Regulation Section 1.280G-1Q/A-24(b) or (c)).
(vi) The
provisions of this Section 4(e) are intended to apply to any and all payments or benefits available to Executive under this
Agreement or any other agreement or plan of the Company under which Executive receives Contingent Compensation Payments. For purposes
of this Section 4(e), the references to Company determinations shall mean determinations made by a nationally recognized law firm,
accounting firm or compensation consulting firm selected by the Company in its reasonable good faith discretion.
5. Proprietary
Rights, Inventions, Non-Competition and Non-Solicitation Agreement.
Executive acknowledges and agrees that Executive
must, as a condition of Executive’s employment, execute, within ten (10) business days following the Effective Date (but in
no event prior to the Effective Date), the Proprietary Rights, Inventions, Non-Competition and Non-Solicitation Agreement attached
hereto as Exhibit E (the “Restrictive Covenants Agreement”) indicating Executive’s agreement to all of Executive’s
obligations thereunder. Executive further acknowledges that the Executive’s receipt of the equity awards as set forth in Section 3(c) above
and Executive’s eligibility for the severance benefits described in Section 4(b) above is contingent on Executive’s
agreement to the post-employment non-competition provisions set forth in the Restrictive Covenants Agreement. Executive further acknowledges
that such consideration was mutually agreed upon by Executive and the Company and is fair and reasonable in exchange for Executive’s
compliance with such non-competition obligations and that Executive was provided at least ten (10) business days to review the Restrictive
Covenants Agreement.
6. Records.
As soon as practicable following termination of Executive’s relationship with the Company, Executive shall deliver to the Company
any property of the Company which may be in Executive’s possession (other than de minimis items) including products, materials,
memoranda, notes, records, reports, or other documents or photocopies of the same, except such Company property as Executive is permitted
to retain pursuant to Section 1(b) of the Restrictive Covenants Agreement. Notwithstanding the foregoing, the Executive shall
be permitted to retain his personal calendar, personal contacts (that existed prior to his employment with the Company) and personal correspondence,
provided that such documents do not contain any Proprietary Information (as defined in the Restrictive Covenants Agreement). Additionally,
Executive shall be permitted to retain any information or documentation reasonably needed for purposes of his tax returns.
7. No
Conflicting Agreements. Executive hereby represents and warrants that Executive has no commitments or obligations inconsistent with
this Agreement.
8. Conditions
to Employment. Executive shall, from time to time during employment as determined by the Company in its sole good faith discretion,
be available for and cooperate with the Company in obtaining background checks on Executive, including providing any and all consents
necessary to the accomplishment of the foregoing. Executive’s employment is also conditioned on Executive’s provision of proof
of Executive’s identity and right to work in the United States, as required by federal law.
9. General.
(a) Notices.
All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party’s
address as follows:
| If to the Company: | Ocular Therapeutix, Inc. |
24 Crosby Drive
Bedford, MA 01730
USA
Attention: VP, Human Resources
Telephone: (781) 357-4000
With an email copy to:
VP,
Human Resources: hr@ocutx.com
VP, Law Department: law@ocutx.com
| If to the Company: | Dr. Pravin
Dugel |
Address on File with the Company
With an email copy to:
Michael S. Katzke
[**]
Joshua M. Miller
[**]
or to such other address as a party may designate
by notice hereunder, and shall be either (i) delivered by hand, (ii) sent by overnight courier, or (iii) sent by registered
or certified mail, return receipt requested, postage prepaid. All notices, requests, consents and other communications hereunder shall
be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of
such party set forth above, (ii) if sent by overnight courier, on the next business day following the day such notice is delivered
to the courier service, or (iii) if sent by registered or certified mail, on the fifth (5th) business day following the day such
mailing is made.
(b) Entire
Agreement. This Agreement, together with any referenced agreements incorporated herein, including the Restrictive Covenants Agreement,
embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all
prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant
or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express
terms and provisions of this Agreement.
(c) Modifications
and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties
hereto.
(d) Waivers
and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written
document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or
shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such
waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute
a continuing waiver or consent.
(e) Assignment.
The Company shall assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the
Company’s business or that aspect of the Company’s business in which Executive is principally involved. Executive may not
assign Executive’s rights and obligations under this Agreement without the prior written consent of the Company. Any amounts otherwise
due to Executive (or his beneficiaries) following his death shall be paid to such beneficiaries or Executive’s estate.
(f) Benefit.
All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall
inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed
to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third-party beneficiary
of this Agreement.
(g) Governing
Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by
the law of the Commonwealth of Massachusetts, without giving effect to the conflict of law principles thereof.
(h) Jurisdiction
and Service of Process. Any legal action or proceeding with respect to this Agreement shall be brought in the courts of the Commonwealth
of Massachusetts or of the United States of America for the District of Massachusetts. By execution and delivery of this Agreement, each
of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid
courts. Each of the parties hereto irrevocably consents to the service of process of any of the aforementioned courts in any such action
or proceeding by the mailing of copies thereof by certified mail, postage prepaid, to the party at its address set forth in Section 9(a) hereof.
(i) Severability.
The parties intend this Agreement to be enforced as written. However, (i) if any portion or provision of this Agreement shall to
any extent be declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement,
or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable,
shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted
by law; and (ii) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the
geographic area covered thereby, the Company and Executive agree that the court making such determination shall have the power to reduce
the duration and/or geographic area of such provision, and/or to delete specific words and phrases (“blue-penciling”), and
in its reduced or blue-penciled form such provision shall then be enforceable and shall be enforced.
(j) Headings
and Captions; Interpretation. The headings and captions of the various subdivisions of this Agreement are for convenience of reference
only and shall in no way modify, or affect the meaning or construction of any of the terms or provisions hereof.
(k) No
Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement,
and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party. No single
or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps
to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any
other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of such
party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle
the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver
of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.
(l) Counterparts.
This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument.
(m) Survival.
The provisions of Sections 4, 6, and 9 shall survive the termination of this Agreement and Executive’s employment hereunder in accordance
with their terms. For the avoidance of doubt, the Restrictive Covenants Agreement and any applicable equity award agreement shall also
survive the termination of this Agreement and Executive’s employment hereunder.
[Remainder of Page Intentionally Left Blank]
IN WITNESS THEREOF, the parties
hereto have executed this Agreement as of the day and year first above written.
Ocular Therapeutix, Inc. |
|
|
|
/s/ Antony Mattessich |
|
Name: |
Antony Mattessich |
|
Title: |
President and Chief Executive Officer |
|
Agreed and Accepted |
|
|
|
/s/ Pravin Dugel |
|
Name: |
Dr. Pravin Dugel |
|
Exhibit 10.4
AMENDMENT
TO EMPLOYMENT AGREEMENT
This First Amendment
(the “First Amendment”) to the Agreement (as defined below) is dated as of February 21, 2024 (the “Effective Date”),
and entered into by and between Ocular Therapeutix, Inc., with offices at 24 Crosby Drive, Bedford, MA 01730 (hereinafter referred to
as “Ocular” or the “Company”), and Antony C. Mattessich (hereinafter referred to as “Executive”).
WHEREAS,
Ocular and Executive entered into that certain Employment Agreement effective as of June 20, 2017, (the “Agreement”);
NOW,
THEREFORE, Ocular and Executive hereby consent and agree to amend the Agreement in accordance with the relevant terms and provisions
thereof as follows:
| 1. | Section
1, “Employment,” shall be amended by deleting paragraph (a) in its entirety and
inserting the following paragraph (a) in lieu thereof: |
(a) Capacity.
During the Term (as defined below), Executive shall serve the Company as Chief Executive Officer of the Company and shall have such duties
and responsibilities as are customary for such position consistent with Executive’s position. The Executive shall report to the
Board and, during such time as there is an Executive Chairman of the Board (“Chairman”), to the Chairman.
| 2. | Section
2, “Term of Employment,” shall be amended by deleting paragraph (c)(ii) in its
entirety and inserting the following paragraph (c)(ii) in lieu thereof: |
(ii) A
material adverse change by the Company in Executive’s duties, authority or responsibilities as Chief Executive Officer of the Company
which causes Executive’s position with the Company to become of materially less responsibility or authority than Executive’s
position immediately following the Commencement Date where such change is not remedied within ten (10) business days after written notice
thereof by Executive, including any failure of the Board to renominate Executive for election as a member of the Board;
| 3. | Section
4, “Severance Compensation,” shall be amended by deleting paragraph (b) in its
entirety and inserting the following paragraph (b) in lieu thereof: |
(b) In
the event that Executive’s employment hereunder is terminated (i) by Executive for Good Reason or (ii) by the Company
without Cause, the Company shall pay to Executive the Accrued Obligations. In addition, the Executive shall be eligible for the severance
benefits set forth in Sections 4(b)(i)-4(b)(iii) below as further described therein. The receipt of any severance benefits provided in
this Section shall be dependent upon Executive’s execution and nonrevocation of a standard separation and general release of claims
agreement, substantially in the form attached hereto as Exhibit A (the “Release”), which Release must be signed and any applicable
revocation period with respect thereto must have expired by the sixtieth (60th) day following Executive’s termination
of employment. The severance payments and benefits shall be paid or commence, as applicable, on the first payroll period following the
date the Release becomes effective (the “Payment Date”). Notwithstanding the foregoing, if the 60th day following
Executive’s termination occurs in the calendar year following the date on which Executive’s employment terminates, then the
Payment Date shall be no earlier than January 1 of such subsequent calendar year.
(i) Base Salary; Bonus. In the event that Executive’s employment is terminated by Executive for Good Reason or by the Company
without Cause, and in either case such termination occurs outside of a Protected Period (as defined below), the Company shall continue
to pay Executive his then base salary, less applicable taxes and withholdings, for twenty-four (24) months following Executive’s
termination in accordance with the Company’s payroll practice, beginning on the Payment Date; provided, that the first installment
will include all amounts that otherwise would have been paid to Executive from the date Executive’s employment terminates through
the Payment Date had the Release become effective on the date of termination. In the event that Executive’s employment is terminated
by Executive for Good Reason or by the Company without Cause, and in either case such termination occurs during the period commencing
on the date ninety (90) days prior to the closing of a Corporate Change and ending twelve (12) month following the closing of such Corporate
Change (the “Protected Period”), the Company shall pay Executive an aggregate amount equal to (A) twenty-four (24) months
of Executive’s then base salary and (B) two times his target annual Bonus for the year in which the termination of employment occurs,
less applicable taxes and withholdings, in a lump sum on the Payment Date. In the event of a termination during the Protected Period
that occurs prior to the occurrence of a Corporate Change such that the Payment Date occurs prior to the occurrence of the Corporate
Change (x) following the occurrence of the Corporate Change, the Company shall pay Executive the Protected Period severance amount following
the Corporate Change, less any severance payments made previously under this Section 4(b)(i) and (y) if necessary to comply with the
provisions of Code Section 409A (as defined below) certain severance payments shall continue to be made in installments.
(ii) Equity
Awards. In the event that Executive’s employment is terminated by Executive for Good Reason or by the Company without Cause,
the following shall apply:
(A) Any
equity grants that vest solely based on Executive’s continued performance of services shall become vested, exercisable and nonforfeitable
as of the Payment Date with respect to the portion of such award that would have vested, become exercisable or become nonforfeitable
within the 12 month period following the date of termination, provided that with respect to any such equity grants awarded to Executive
prior to February 21, 2024 (the “Current Grants”), the portion of such awards that would have vested, become exercisable
or become nonforfeitable with the 24 month period following the date of termination shall be come vested, exercisable and nonforfeitable
as of the Payment Date . Notwithstanding the foregoing, if the termination occurs during the Protected Period, one hundred percent (100%)
of Executive’s then outstanding unvested equity awards that vest solely based on Executive’s continued performance of services
shall vest, become exercisable and nonforfeitable, as of the Payment Date.
(B) Any
Current Grants that are in the form of stock options shall be exercisable for a period of 24 months following the date of termination.
(C) For
the avoidance of doubt, any equity awards that vest based on the achievement of performance metrics shall be governed by the terms of
the applicable award agreement and shall not be entitled to accelerated vesting pursuant to this Agreement.
(iii) COBRA.
The Company shall continue to provide Executive and his then enrolled eligible dependents with group health insurance and shall continue
to pay the amount of the premium as in effect on the date of such termination for the eighteen (18) month period following the effective
date of such termination, subject to applicable law and the terms of the respective policies; provided that the Company’s obligation
to provide the benefits contemplated herein shall terminate upon Executive’s becoming eligible for coverage under the medical benefits
program of a subsequent employer. The foregoing shall not be construed to extend any period of continuation coverage (e.g., COBRA) required
by Federal law.
4. Executive
consents to the change in his reporting structure resulting from the Company appointing an Executive Chairman and agrees that such change
will not be considered a material adverse change by the Company in Executive’s duties, authority or responsibilities for purposes
of the Agreement and shall not constitute Good Reason under the Agreement.
This First Amendment constitutes an
amendment to the Agreement. In the event the terms of this First Amendment conflict with any provision of the Agreement, the terms of
this First Amendment shall control. Executive understands that, except as explicitly set forth above, the terms and conditions of the
Agreement shall continue in full force and effect.
This First Amendment may
be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
IN WITNESS
WHEREOF, the parties hereto have duly executed this First Amendment to be effective as of the Effective Date.
Ocular Therapeutix, Inc. |
|
Executive |
|
|
|
|
|
|
By: |
/s/ Charles Warden |
|
By: |
/s/ Antony Mattessich |
Name: |
Charles Warden |
|
Name: |
Antony Mattessich |
Title: |
Chairman |
|
Title: |
Chief Executive Officer |
|
|
|
|
|
|
Dated: 2/21/2024 |
|
Dated: 2/21/2024 |
Exhibit 10.5
OCULAR THERAPEUTIX, INC.
Amendment No. 2 to 2019 Inducement Stock Incentive
Plan
Ocular Therapeutix, Inc’s 2019 Inducement
Stock Incentive Plan (the “Plan”), pursuant to Section 11(d) thereof, is hereby amended as set forth below.
The first sentence of Section 4(a) of the Plan be, and hereby is, deleted
in its entirety and replaced with the following in lieu thereof:
“Subject to adjustment under Section 9, Awards may be made under
the Plan for up to 3,804,000 shares of common stock, $0.0001 par value per share, of the Company (the “Common Stock”).”
Adopted by the Board of Directors: February 20, 2024
Exhibit 99.1
Ocular Therapeutix, Inc.
Announces $325.0 Million Private Placement
BEDFORD,
MA, February 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical
company committed to enhancing people’s vision and quality of life through the development and commercialization
of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a securities purchase agreement
with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately
$325.0 million, before deducting placement agent fees and other offering expenses.
The private placement includes participation
by new and existing investors, including Venrock Healthcare Capital Partners, TCGX, Deep Track Capital, Perceptive Advisors, Great Point
Partners, LLC, Logos Capital, Surveyor Capital (a Citadel company), Acuta Capital Partners, Opaleye Management and a large life sciences
dedicated investor, among others.
In the private
placement, the Company is selling 32,413,560 shares of its common stock at a price of $7.52 per share and, in lieu of common stock to
certain investors, pre-funded warrants to purchase up to an aggregate of 10,805,957 shares of its common stock at a price of $7.519 per
pre-funded warrant. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and remains
exercisable until exercised in full. The private placement is expected to close on February 26, 2024, subject to the satisfaction
of customary closing conditions.
BofA Securities
is acting as sole placement agent to the Company in connection with the private placement.
The Company
intends to use the net proceeds from the private placement, together with its existing cash and cash equivalents, to accelerate the clinical
development of AXPAXLI™ for the treatment of wet AMD, including its ongoing SOL-1 pivotal Phase 3 clinical trial and its planned
SOL-2 Phase 3 clinical trial; to support its other clinical development programs; and for working capital and other general corporate
purposes.
The securities
being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States
absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other
jurisdictions’ securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission
(the “SEC”) registering the resale of the shares of common stock issued in the private placement and the shares of common
stock issuable upon the exercise of the pre-funded warrants issued in the private placement no later than the 30th day after the closing
of the private placement.
This press
release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer,
solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering
of the securities under the resale registration statement will only be made by means of a prospectus.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical
company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye
using its proprietary bioresorbable hydrogel-based formulation technology ELUTYX™. Ocular Therapeutix’s first commercial
drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following
ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets
include: AXPAXLI™ (axitinib intravitreal implant), currently in a pivotal Phase 3 trial for the treatment of wet AMD and a Phase
1 clinical trial for the treatment of diabetic retinopathy; PAXTRAVA™ (travoprost intracameral implant, also known as OTX-TIC),
currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (cyclosporine
intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials.
Forward-Looking Statements
Any statements in this press release
about future expectations, plans, and prospects for the Company, including the Company’s expectations and plans regarding the private
placement; the Company’s expected closing of the private placement and whether the conditions for the closing of the private placement
will be satisfied; the Company’s anticipated use of its existing cash and cash equivalents and the proceeds from the private placement;
and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue,”
and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors.
Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development
programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, uncertainties related to market conditions; whether the conditions for
the closing of the private placement will be satisfied; and other factors discussed in the “Risk Factors” section contained
in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking
statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates
that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as required
by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent
to the date of this press release.
Contacts:
Investors
Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com
or
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
v3.24.0.1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2023 to Apr 2024